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ABSTRACT 
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by  
 
Anu Singh Maharjan 
 
 
 Immune cells such as neutrophils and monocytes enter tissues after tissue 
damage and clear cell debris to allow repair cells such as fibroblasts to close the 
wound.  Monocytes also differentiate into fibroblast-like cells called fibrocytes to 
mediate wound healing, similar to fibroblasts. However, in abnormal wound 
healing such as acute respiratory distress syndrome (ARDS) and fibrosing 
diseases, the accumulation of immune cells such as neutrophils or fibrocytes 
become detrimental to health.  In ARDS, neutrophils accumulate in the lungs and 
causes additional damage by producing reactive oxygen species (ROS).  In 
fibrosing diseases, increased fibrocyte differentiation is one of the causes that 
increase extracellular matrix deposition, which leads to severe scar tissue build 
up.  Since there are no effective treatments for ARDS or fibrosing diseases, 
understanding the regulation of neutrophil activation or fibrocyte differentiation 
could be helpful to develop new effective therapies.   
 
 The Gomer lab has found several factors that either promote or inhibit 
fibrocyte differentiation.  The pro-fibrotic cytokines such as IL-4 and IL-13 
potentiate fibrocyte differentiation while the plasma protein serum amyloid P 
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(SAP), crosslinked IgG, and the pro-inflammatory cytokines IFN-γ and IL-12 
inhibit fibrocyte differentiation.  In this thesis, I have now shown that additional 
factors such as toll-like receptor 2 (TLR2) agonists and low molecular weight 
hyaluronic acid (LMWHA) inhibit fibrocyte differentiation, while high molecular 
weight hyaluronic acid (HMWHA) potentiate fibrocyte differentiation. 
 
The accumulation of neutrophils in the lungs is one of the major factors 
that debilitate the health of a patient in ARDS.  Since neutrophils have Fc 
receptors, I examined the effect of SAP on neutrophil spreading, adherence, 
activation, and accumulation.  SAP inhibits neutrophil spreading induced by cell 
debris and TNF-α induced neutrophil adhesion, but SAP is unable to have any 
effect on classic neutrophil adhesion molecules or the production of hydrogen 
peroxide.  SAP inhibits neutrophil accumulation in the lungs of bleomycin-injured 
mice.  There is an exciting possibility of using SAP as a therapeutic agent to treat 
ARDS. 
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Chapter 1: Fibrocytes in wound healing and fibrosing diseases, and 
neutrophil activation in acute respiratory distress syndrome (ARDS) 
 
1.1 Overview and Significance 
 
Fibrosing diseases and acute respiratory distress syndrome (ARDS) are 
major medical problems in many western countries (King et al., 2011; Perez et 
al., 2003; Wheeler and Bernard, 2007).  A patient comes into the hospital with an 
abrasion on his legs, and within 12 hours, he has a hard time breathing and has 
to be put on a ventilator.  He dies within 24 hours after being admitted since he is 
unable to breathe and has 90% influx of neutrophils in his lungs compared to a 
normal healthy human lungs (Bastarache and Blackwell, 2009).  This is one 
example of the 400,000 cases of acute lung injury (ALI) or its severe form called 
acute respiratory distress syndrome (ARDS) that affects many people in the 
United States.  ALI/ARDS is a condition where a patient has severe breathing 
problem and a huge influx into the lungs of a type of white blood cell called 
neutrophils.  About 74,500 patients die each year from this disease, and the 
survivors develop long-term pulmonary fibrosis.  There is only a 30% survival rate 
after being diagnosed with pulmonary fibrosis (King et al., 2011; Perez et al., 
2003).  Fibrosing diseases are characterized by scar tissue build-up, which result 
from excessive production of extracellular matrix proteins such as collagen and 
fibronectin (Wynn, 2007).  Circulating monocyte-derived cells called fibrocytes 
have been implicated in the formation of fibrotic lesions and can potentially 
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differentiate into collagen producing cells or activate fibroblasts to produce more 
collagen (Reilkoff et al., 2011).  Little is known about the progression of 
ALI/ARDS or fibrosing diseases.  Therefore, understanding how wound healing 
strays away from normal healing to aberrant healing is a fundamental question in 
reparative medicine.  In this research, I try to understand the biology of wound 
healing in terms of monocyte to fibrocyte differentiation and the role of 
neutrophils in acute inflammation. 
 
The process of wound healing begins immediately after tissue injury.  
There is a systematic process in which different immune cells such as 
neutrophils and monocytes clear the wound to aid repair cells such as fibroblasts 
to repair the injured sites (Piantadosi and Schwartz, 2004).  Monocyte-derived 
cells called fibrocytes participate in wound healing (Abe et al., 2001; Bucala, 
1994; Gomperts and Strieter, 2007).  In an unchecked wound healing process, 
there is an excessive accumulation of extracellular matrix proteins and one of the 
culprits for this deposition is fibrocytes (Bellini and Mattoli, 2007a; Mattoli et al., 
2009; Strieter et al., 2009b).  In our laboratory, we try to understand the biology 
of monocyte to fibrocyte differentiation and find potential therapies that can either 
inhibit or potentiate fibrocyte differentiation.  Potentiation of fibrocyte 
differentiation is beneficial for people, such as diabetic patients, who have 
difficulty healing wounds (Ferreira et al., 2006).  On the other hand, inhibition of 
fibrocyte differentiation is beneficial for patients who have excess scar tissue 
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build up because of fibrocytes (Barth et al., 2002; Bellini and Mattoli, 2007a; 
Haudek et al., 2006; Quan et al., 2004).  
 
In this thesis, I elucidate the biology of fibrocyte differentiation in chapters 
2 and 3.  In chapter 2, I examined the different pathogen-associated molecular 
patterns and their roles in fibrocyte differentiation.  I show that when human 
peripheral blood mononuclear cells (PBMC) are cultured with toll-like receptor 2 
(TLR2) agonists, monocyte to fibrocyte differentiation is inhibited.  The TLR2 
agonists appear to stimulate some cells in the PBMC population to secrete a 
signal that inhibits the ability of purified monocytes to differentiate into fibrocytes. 
This signal is not IFN-γ, IFN-α, aggregated IgG, or serum amyloid P, signals 
known to directly inhibit the differentiation of monocytes to fibrocytes.  These 
results identify a novel mechanism used to regulate the differentiation of 
monocytes to fibrocytes.  I also examined endogenous danger signals that can 
affect monocyte to fibrocyte differentiation.  In chapter 3, I have examined an 
extracellular matrix component called hyaluronic acid and how it affects 
monocyte to fibrocyte differentiation.  In healthy tissues, hyaluronic acid is 
present as high molecular weight polymers, while in fresh wounds and fibrotic 
lesions, hyaluronic acid breaks down to low molecular weight polymers.  In this 
research, I show that high molecular weight hyaluronic acid potentiates fibrocyte 
differentiation while low molecular weight hyaluronic acid inhibits fibrocyte 
differentiation.   
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In the early phase of wound healing, termed as acute inflammation, 
immune cells such as neutrophils and monocytes enter the injured sites.  In a 
normal wound healing situation, these immune cells are cleared out of the wound 
site after accomplishing their tasks of engulfing bacteria or clearing out cell 
debris.  However, in acute lung injury (ALI) or acute respiratory distress 
syndrome (ARDS), immune cells such as neutrophils accumulate in the injured 
site and cause additional damage to the wound.  In our laboratory we found that 
the plasma protein serum amyloid P (SAP) can inhibit fibrocyte differentiation 
through Fc receptors.  Since neutrophils also have Fc receptors, I examined the 
effect of SAP on neutrophils in vitro and in vivo.  Neutrophil activation leads to 
increased adherence, increased surface levels of the adhesion molecules, 
increased production of hydrogen peroxide, and increased accumulation of 
neutrophils in bleomycin treated mice lungs (Montecucco et al., 2008; Nathan et 
al., 1989; Nathan, 1987, 1989; Weisbart et al., 1985; Weisbart et al., 1982; Yong 
et al., 1992).  In chapter 4, I show that SAP diminishes the adhesion of 
neutrophils, but has no effect on classic neutrophil adhesion molecules or the 
production of hydrogen peroxide.  I also show that SAP inhibits the accumulation 
of neutrophils in bleomycin treated mice lungs.  
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1.2 Tissue Injury and Wound Healing 
 
Following tissue injury, local repair cells called fibroblasts proliferate to 
repair the wound (Martin, 1997; Singer and Clark, 1999).  In addition to 
fibroblasts, circulating peripheral blood cells such as neutrophils, monocytes, 
dendritic cells and lymphocytes leave the bloodstream and enter the injured site. 
Once monocytes are in the injured site, they can differentiate into fibroblast-like 
cells called fibrocytes that also aid in healing (Abe et al., 2001; Bucala, 1994; 
Gomperts and Strieter, 2007; Haudek et al., 2006; Pilling et al., 2003; Pilling et 
al., 2006; Quan et al., 2004; Yang et al., 2002).  Fibrocytes can differentiate from 
purified CD14+ peripheral blood monocytes, but fibrocytes lose expression of 
CD14 (Abe et al., 2001; Maharjan et al., 2010; Pilling et al., 2003; Shao et al., 
2008; Yang et al., 2002).  Other studies also suggest that fibrocytes differentiate 
from a population of bone-marrow derived CD45+ CXCR4+ cells found in 
peripheral blood (Phillips et al., 2004; Reilkoff et al., 2011; Strieter et al., 2009a).  
Fibrocytes are spindle-shaped cells that express hematopoietic cell markers such 
as MHC class II, CD34, CD45RO, 25F9, and S100A8/A9, stromal cell markers 
such as collagen I, and collagen III, and chemokine receptors such as CCR2, 
CXCR4, and CCR7 that mediate their entry into the site of injury (Bucala, 1994; 
Chesney, 1997; Hashimoto et al., 2004; Moore et al., 2005; Phillips et al., 2004; 
Pilling et al., 2009).  Fibrocytes produce cytokines, collagens, angiogenic and 
fibrogenic growth factors, and matrix metalloproteinases that help to rebuild 
tissue after injury (Abe et al., 2001; Bucala, 1994; Gomperts and Strieter, 2007; 
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Hartlapp et al., 2001; Mori et al., 2005; Quan et al., 2004; Wang et al., 2007b; 
Yang et al., 2002).  Fibrocytes are found as a circulating population of cells 
present in the peripheral blood, and there are elevated numbers of fibrocytes in 
patients with inflammatory and fibrotic diseases (Bellini and Mattoli, 2007b; 
Mattoli et al., 2009; Strieter et al., 2009a).   
 
1.3 Fibrosing diseases 
The inability to form scar tissues in chronic wounds, and the unwanted 
appearance of scar tissue in fibrosing diseases, are major medical problems.  In 
many western countries, fibrosing diseases like congestive heart failure, kidney 
failure, cirrhosis of the liver, idiopathic pulmonary fibrosis, and scleroderma cause 
chronic and fatal disorders in many people (King et al., 2011; Perez et al., 2003; 
Wynn, 2007).  Fibrosis is described as an out of control wound repair that leads 
to an excessive growth of repair tissue. In cases of repeated injuries, 
inflammation and repair processes alters the cytokine level, which causes a 
failure to degrade extracellular matrix (ECM) proteins, and therefore, leads to 
increased deposition of ECM and thus fibrosis (Cohn et al., 2004; Powell et al., 
1999; Wynn, 2004).  
 
1.4 Role of fibrocytes in fibrosing diseases 
Recent studies show the role of fibrocytes not only in wound repair, but 
also in diseases like breast cancer, scleroderma, and pulmonary fibrosis and 
  7 
congestive heart failure (Barth et al., 2002; Haudek et al., 2006; Quan et al., 
2004; Schmidt et al., 2003).  Therefore, inhibiting fibrocytes could be a way to 
reduce the excessive ECM formation in most of these diseases.   
 
1.5  Factors that regulate fibrocyte differentiation 
We found that the plasma protein serum amyloid P (SAP) can directly 
inhibit monocytes from differentiating into fibrocytes (Pilling et al., 2003).  Purified 
SAP inhibits fibrocyte differentiation, but other serum proteins such as serum 
amyloid A and C-reactive protein (CRP) are unable to inhibit the differentiation of 
monocytes into fibrocytes (Pilling et al., 2003; Pilling, 2007).  The profibrotic 
cytokines interleukin  (IL)-4 and IL-13 directly activate monocytes to differentiate 
into fibrocytes, while cross-linked immunoglobulin G (IgG) and the 
proinflammatory cytokine interferon (IFN)-γ directly inhibit the differentiation of 
monocytes into fibrocytes (Haudek et al., 2006; Shao et al., 2008).  Another 
proinflammatory cytokine, IL-12, activates some cells in the peripheral blood 
mononuclear cell (PBMC) population, possibly natural killer (NK) cells, to 
indirectly inhibit fibrocyte differentiation (Shao et al., 2008).  In human PBMC 
culture, IFN-α2b inhibits fibrocyte differentiation, but whether this acts directly on 
monocytes is unknown (Chang et al., 2007).  Other regulators of fibrocytes 
include the adenosine A2A receptor and cysteinyl leukotriene receptor 1 (CysLT1) 
(Katebi et al., 2008; Vannella et al., 2007).  The adenosine A2A receptor regulates 
cell proliferation and cytokine production, and blocking this receptor inhibits the 
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recruitment of fibrocytes in bleomycin-treated mouse skin (Katebi et al., 2008). 
CysLT1 is a receptor for lipid mediators which promote fibroblast proliferation, 
fibroblast chemotaxis and collagen synthesis (Vannella et al., 2007).  In mice with 
fluorescein isothiocyanate (FITC)-induced lung fibrosis, blocking CysLT1 inhibits 
the appearance of fibrocytes (Vannella et al., 2007).  
 
It is unclear why some of the above factors affect fibrocyte differentiation. 
However, we hypothesized that SAP prevents fibrocyte differentiation in the 
circulation and that aggregated IgGs prevent fibrocyte differentiation because 
aggregated IgGs signify the presence of infection.  We hypothesized that after 
monocytes detect an infected wound, monocytes do not differentiate into 
fibrocytes, since closing an infected wound could cause further damage such as 
gangrene, an infectious wound closure that results in further decay of the 
surrounding cells (Ferreira et al., 2006; Safioleas et al., 2006). 
 
1.6 Acute respiratory distress syndrome (ARDS)/acute lung injury (ALI) 
Smoke inhalation, for instance from house fires, can lead to severe lung 
damage called acute lung injury (ALI) or acute respiratory distress syndrome 
(ARDS).  ARDS can be caused by infection, sepsis, aspiration (for example 
stomach contents), and trauma to the lungs.  In a typical case, a patient develops 
severe breathing problems 48 to 96 hours after the smoke inhalation.  In the 
United States, there are 400,000 cases of ALI/ARDS per year (Baudouin, 2004; 
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Chabot et al., 1998; Piantadosi and Schwartz, 2004).  Due to the lack of effective 
treatments, the mortality rate remains as high as 40% (Wheeler and Bernard, 
2007).   
 
In many ALI/ARDS patients, huge amounts of debris from damaged lung 
cells causes a massive accumulation of activated neutrophils into the lungs 
(Chollet-Martin et al., 1996; Chopra et al., 2009; Weiland et al., 1986). 
Unfortunately, this massive influx of activated neutrophils is one of the major 
factors that contribute to the progression of the disease (Segel et al., 2011).  
Activated neutrophils continue to release reactive oxygen species and proteases 
that damage the remaining lung cells, causing a vicious cycle of damage, 
neutrophil influx and activation, and further neutrophil-induced damage (Perl et 
al., 2008; Segel et al., 2011).   
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Chapter 2: Toll-like receptor 2 agonists inhibit human fibrocyte 
differentiation 
 
 
2.1 Introduction 
 
The immune system can recognize pathogens using Toll-like receptors 
(TLRs) (Akira et al., 2003; Beutler, 2009; Hawn et al., 2007; Janeway and 
Medzhitov, 2002; Medzhitov and Janeway, 2000; Medzhitov and Janeway, 1999; 
Trinchieri and Sher, 2007).  There are 11 different TLRs in humans and 16 
different TLRs in mouse (Figure 2.1).  TLR agonists include pathogen-specific 
molecules such as lipopolysaccharides (LPS) from gram-negative bacteria 
(recognized by TLR4), flagellin from bacteria (recognized by TLR5), single-
stranded DNA (ssDNA) from viruses (recognized by TLR8), and unmethylated 
DNA from bacteria (recognized by TLR9) (Janeway and Medzhitov, 2002; 
Medzhitov and Janeway, 1998).  TLR2 recognizes a wide variety of molecular 
patterns such as peptidoglycan, lipotechoic acid, and lipoproteins from gram-
positive bacteria, zymosan from the yeast cell wall, and lipoarabinomannan from 
mycobacteria (Hawn et al., 2007; Lien et al., 1999; Medzhitov and Janeway, 
2000; Yoshimura et al., 1999).  TLRs 1, 2, 4, 5, and 6 are specialized to 
recognize bacterial products and are situated on the plasma membrane of a cell 
(Figure 2.1.1).  Most of the TLRs homodimerize and recognize the microbial 
molecular patterns, except for TLR2.  TLR2 can heterodimerize with either TLR1 
or TLR6 and recognize different bacterial lipoproteins (Lien et al., 1999; 
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Yoshimura et al., 1999). TLR2 heterodimerizes with TLR1 and detects triacylated 
lipoprotein, whereas TLR2 detects diacylated lipoprotein as it forms a 
heterodimer with TLR6.  This gives TLR2 a unique ability to detect various 
bacterial patterns.  On the other hand, TLRs 3, 7, 8, and 9 are specialized to 
detect viral compounds such as viral DNAs and ssRNAs, and these receptors are 
localized in intracellular compartments (Figure 2.1.1).  TLR signaling pathways 
trigger innate immune responses through nuclear factor (NF)-κB-dependent and 
IFN-regulatory factor-dependent pathways (Trinchieri and Sher, 2007).  
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Figure 2.1.1 The toll-like receptors (TLRs) and their pathogen specific recognition 
patterns (modified from (Takeda and Akira, 2004)).  TLRs 1, 2, 4, 5, and 6 are 
located on the plasma membrane of the cell and these TLRs are specialized to 
recognize bacterial peptides and lipopolysaccharides.  TLRs 3, 7, 8, and 9, on 
the other hand, are located in the endosomal compartments and these TLRs are 
specialized to recognize various viral nucleic acids.  
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TLRs are present in many immune cells such as NK cells, dendritic cells, 
monocytes, B cells, and T cells (Table 2.1.1) (Hornung et al., 2002; Zarember 
and Godowski, 2002).  
 
Table 2.1.1 mRNA expression of TLR1-10 in different immune cells* 
(Hornung et al., 2002; Zarember and Godowski, 2002). 
 Monocytes Plasmacytoid 
Dendritic 
Cells 
NK cells B cells T cells 
TLR1 Moderate Low High High Moderate 
TLR2 High  None Moderate Low Low 
TLR3 None None Moderate None Low 
TLR4 High None Low Low None 
TLR5 Moderate None Moderate None Moderate 
TLR6 Low Low Moderate High Low 
TLR7 Low Moderate Low Low Low 
TLR8 Moderate None Low None Low 
TLR9 Low High Low Moderate Low 
TLR10 None Low Low Moderate None 
 
*The intensity of the mRNA expression levels of TLRs in monocytes, plamacytoid 
dendritic cells, NK cells, B cells, and T cells is shown.  
 
From our previous studies, we hypothesized that aggregated IgG and SAP 
signal monocytes of the presence of sepsis, and therefore, prevents wound 
closure by inhibiting fibrocyte differentiation.  Since TLRs are present on 
monocytes (Table 2.1.1) and they too recognize the presence of infection, we 
examined whether TLR agonists could also affect the differentiation of monocytes 
into fibrocytes. 
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2.2 Methods 
2.2.1 Culturing PBMC with TLR agonists or IFN-α 
Blood was collected from healthy adult volunteers in accordance with specific 
approval of Rice Universityʼs Institutional Review Board. Written consent was 
received from all volunteers, and all samples were deidentified before analysis. 
PBMCs were isolated and incubated in serum-free media (SFM) as described 
previously (Pilling et al., 2003; Pilling et al., 2006; Pilling et al., 2009; Shao et al., 
2008). TLR agonists (Invivogen, San Diego, CA, USA) were reconstituted in 
endotoxin-free water (Invivogen). All experiments were done with at least three 
different batches of agonists. IFN-α was obtained from EMD-Calbiochem 
(Darmstadt, Germany). A dilution series of TLR agonists (or the same volume of 
water as a control) was made in serum-free medium. A quantity of 100 μl of 
serum-free medium, TLR agonist or IFN-α dilution, or water dilution, was added 
to duplicate wells of a 96-well tissue culture plate (BD Biosciences, San Jose, 
CA, USA). A quantity of 100 µl of human PBMCs at a concentration of 5 × 105 
cells/ml in serum-free medium was then added to each well. On day 5, fields of 
PBMCs were photographed using a phase-contrast microscope, and the number 
of cells per image was counted.  Cells were then fixed and stained, and 
fibrocytes were counted as previously described (Pilling et al., 2003; Pilling et al., 
2006; Pilling et al., 2009; Shao et al., 2008). 
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2.2.2 Preparation of monocytes 
Monocytes were purified from 5 × 107 PBMCs using an EasySep Monocyte 
Depletion Kit (catalog no. 19059; StemCell Technology, Vancouver, BC, Canada) 
according to the manufacturerʼs instructions. To determine the purity of the 
monocytes, cells were analyzed using flow cytometry (FACScan, BD 
Biosciences; or Accuri C6 cytometer, Accuri Cytometers Inc., Ann Arbor, MI, 
USA) as described previously (Shao et al., 2008). A sample of each monocyte 
preparation was stained with 5 μg/ml primary antibodies against the T cell marker 
CD3, the monocyte marker CD14, the NK cell marker CD16, the B cell marker 
CD19 and the leukocyte marker CD45 as previously described (Shao et al., 
2008). Monocytes obtained were greater than 95% pure as determined by the 
expression of CD14. Monocytes were 99% CD45-positive, 0.93% CD3-positive, 
0.93% CD16-positive and 1% CD19-positive. To assess the effect of TLR2 
agonists on monocytes, 5 μl of TLR2 agonist or water were added to 245 μl of 
serum-free medium. A quantity of 100 μl of serum-free medium, TLR2 agonist 
dilution or water dilution was added to a well of a 96-well plate, with each 
condition represented in duplicate wells. A quantity of 100 μl of purified human 
monocytes at a concentration of 5 × 105 cells/ml in serum-free medium was then 
added to each well. Fibrocytes were fixed, stained and counted after monocytes 
were cultured for 5 days. 
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2.2.3 Treating monocytes with conditioned media from PBMC stimulated with 
TLR2 agonists 
To make conditioned medium, a dilution of TLR2 agonists was made as 
described above. A quantity of 100 μl of either SFM, the TLR2 agonist dilution or 
the corresponding water dilution was added to duplicate wells of a 96-well plate 
along with 100 μl of PBMCs at a concentration of 5 × 105 cells/ml in SFM. After 3 
days of incubation, 180 μl of the conditioned media from one well representing 
each condition were transferred into an Eppendorf tube, snap-frozen in liquid 
nitrogen and stored at -20°C. For the well from which the medium was not 
removed, at day 5 the fibrocytes were fixed, stained and counted as previously 
described (Pilling et al., 2003; Pilling et al., 2006; Shao et al., 2008). Also on day 
5, monocytes were prepared from the same donor as described above. A 
quantity of 50 μl of monocytes at a concentration of 1 × 106 cells/ml was 
incubated with 50 μl of the day 3 conditioned medium. After 5 days, cells were 
fixed and stained, and the number of fibrocytes was counted. 
 
2.2.4 Detection of cytokines and SAP by enzyme-linked immunosorbent assay 
The day 3 conditioned media were analyzed for IFN-α, IFN-γ and IL-12 using 
enzyme-linked immunosorbent assay (ELISA) according to the manufacturerʼs 
instructions (Peprotech, Rocky Hill, NJ, USA). The day 3 conditioned media were 
also analyzed for IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, 
granulocyte colony-stimulating factor (G-CSF) and transforming growth factor 
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(TGF)-β1 using a multi-analyte profiler ELISArray kit according to the 
manufacturerʼs instructions (SABiosciences, Frederick, MD, USA). 
 
The day 3 conditioned media were also analyzed for SAP as described 
previously (Pilling et al., 2003; Pilling et al., 2007), with the exception that the 
ELISA plates were coated overnight at 4°C with mouse antihuman SAP antibody 
(SAP-5; Sigma, St. Louis, MO, USA) diluted 1:1,000 in phosphate-buffered saline 
(PBS) instead of 50 mM sodium carbonate buffer, and undiluted day 3 
conditioned media were assayed. 
 
2.2.5 Staining PBMC with CD86 or MHC Class II 
Human PBMCs were cultured in the presence or absence of 8.9 μg/mL TLR3 
agonist Poly (I:C), 0.89 μg/mL TLR7 agonist imiquimod (IMIQ), or 2.0 μg/ml 
nucleotide oligomerization domain (NOD)-like receptor (NLR) agonist 
peptidoglycan (PGN) in 1 ml in the well of a 48-well plate.  On day 1 or 3, 900 μl 
of the conditioned media were carefully pipetted out and transferred into an 
Eppendorf tube, snap-frozen in liquid nitrogen and stored at -20°C.  A quantity of 
500 μl of ice-cold 50 mM ethylenediaminetetraacetic acid (EDTA) in PBS was 
then added to the PBMCs for 5 minutes at 4°C. The cells were vigorously 
resuspended with a plastic transfer pipette. The cells were transferred into an 
Eppendorf tube, collected by centrifugation at 300 × g for 5 min and the 
supernatant was discarded. The remaining cells on the plates were washed with 
  18 
1 ml of ice-cold PBS, and this solution was added to the first pellet of cells. The 
cells were again collected by centrifugation at 300 × g for 5 min and then 
resuspended in 200 μl of 4% bovine serum albumin (BSA) in PBS. Cells treated 
with TLR agonists were divided into two separate Eppendorf tubes. The cells 
were incubated with 5 μg/ml antihuman CD86 or 5 μg/ml antihuman Human 
leukocyte antigen-DR/DP/DQ (HLA-DR/DP/DQ) (MHC class II) (both from BD 
Biosciences) for 30 min at 4°C as described previously (Pilling et al., 2009 ). 
Meanwhile, untreated cells were divided into three separate Eppendorf tubes. 
These cells were incubated with 5 µg/ml antihuman CD86 or 5 μg/ml antihuman 
HLA-DR/DP/DQ, or they were kept in 4% BSA in PBS for 30 min at 4°C. All of the 
cells were washed three times in 1 ml of ice-cold PBS and then incubated with 
2.5 μg/ml goat antimouse FITC (Southern Biotechnology, Birmingham, AL, USA) 
for 30 min at 4°C as described previously (Pilling et al., 2009 ). After washing the 
cells three times in 1 ml of ice-cold PBS, the cells were resuspended in 100 μl of 
4% BSA-PBS, and the staining was analyzed using flow cytometry with an Accuri 
C6 cytometer (Accuri Cytometers Inc.).  
 
2.2.6 Detection of Ig molecules by Western blot analysis 
Human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) 
was diluted to 10 μg/ml, 1 μg/ml and 0.1 μg/ml in PBS.  A quantity of 10 μl of 
conditioned media from day 3 or diluted human IgG was mixed with 2.5 μl of 
sodium dodecyl sulfate (SDS) sample buffer containing 20 mM dithiothreitol 
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(DTT) and heated to 100°C for 5 min.  After electrophoresis of the samples on 4-
15% Tris-glycine polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA, 
USA), proteins were transferred to polyvinylidene difluoride (PVDF) membranes 
(Millipore, Bedford, MA, USA) in Tris-NaCl-SDS buffer containing 20% methanol. 
Western blot staining was performed as described previously (Pilling et al., 
2003), with the exception that the detection antibody was 0.05 μg/ml biotinylated 
goat Fab′(2) antihuman Ig (H+L) (Southern Biotechnology) followed by 1:5,000 
ExtrAvidin-Peroxidase staining (Sigma). 
 
2.2.7 Treating monocytes with different combinations of cytokines  
After analyzing the day 3 conditioned media with multi-analyte ELISArray kits, we 
calculated the concentrations of IL-6, IFN-γ, TNF-α, G-CSF, and TGF-β1 in LTA 
(TLR2 agonist)-treated conditioned media, LPS (TLR4 agonist)-treated 
conditioned media and control conditioned media. Cocktails of cytokines 
corresponding to twice the observed concentrations were made in SFM. A 
quantity of 100 μl of purified human monocytes at a concentration of 5 × 105 
cells/ml were incubated in 100 μl of SFM, 100 μl of the above cytokine cocktails 
or 100 μl of the cytokine cocktail with all five of the above cytokines at either 
2,000 pg/ml, 1,000 pg/ml, 200 pg/ml or 20 pg/ml. After 5 days, cells were fixed 
and stained, and fibrocytes were counted. 
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2.2.8 Statistics 
Statistical analysis was performed using GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA).  Statistical significance was determined using 
either anyalysis variance (ANOVA) or a t-test, and significance was defined as P 
<  0.05.  
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2.3 Results 
2.3.1 TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 agonists do not inhibit the 
differentiation of PBMCs to fibrocytes 
To investigate the role of TLR agonists on fibrocyte differentiation, human 
PBMCs were cultured in the presence of various TLR agonists. Since immune 
cells can affect each other, we used PBMCs instead of purified monocytes to 
more closely mimic a human immune system. All of the TLR agonists were 
reconstituted in endotoxin-free water, and a control series of water dilutions had 
no discernible effect on fibrocyte differentiation (data not shown). 
 
All TLR agonists were used in dose ranges that had induced responses in 
previous studies (Table 2.3.1). TLR3, TLR7, TLR8 and TLR9 agonists consisted 
of viral, bacterial or synthetic nucleic acids that stimulated their corresponding 
receptors. When added to PBMCs, none of these agonists showed any 
significant effect on fibrocyte differentiation (Figures 2.3.1 and 2.3.2). The TLR9 
agonist Escherichia coli ssDNA appears to decrease fibrocyte differentiation at 
10 μg/ml (Figure 2.3.2B), but it was not significant by either ANOVA or t-test. One 
batch of the TLR7 agonist IMIQ inhibited fibrocyte differentiation at 3.3 μg/ml, but 
other batches of IMIQ from the same manufacturer had no significant effect on 
fibrocyte differentiation. Although TLR3, TLR7, TLR8 and TLR9 agonists do not 
affect fibrocyte differentiation, the TLR8 agonist ssRNA and the TLR9 agonist 
ODN2006 that we used for these studies induced extracellular TNF-α 
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accumulation by PBMCs (Figure 2.3.3A). TLR3 and TLR7 agonists do not 
significantly enhance the production of TNF-α, but the TLR3 agonist Poly (I:C) 
significantly increased the number of CD86-positive cells at day 1 (Figure 2.3.3B) 
and the TLR7 agonist IMIQ significantly increased the number of HLA-DR/P/Q 
(MHC class II)-positive cells at day 3 (Figure 2.3.3C), which suggest that these 
agonists still have biological effects on PBMCs. 
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Table 2.3.1. TLR agonists stimulate different cytokines and effectors in 
various cell typesa 
 
Agonist TLR Concentration 
used 
Cell type Effect References 
 
Pam3CSK4 (synthetic) 
 
TLR2 
 
0.30 μg/ml 
 
PBMC 
 
Induction of IL-
6 
 
(Taylor et al., 
2006) 
Lipomannan M. 
smegmatis (LM-MS) 
TLR2 10 μg/ml PBMC Cellular 
aggregation 
(Puissegur et 
al., 2007) 
Heat-killed Listeria 
monocytogenes 
(HKLM) 
TLR2 3 x 107 cells/ml PBMC Induction of 
type I and type 
II IFN 
(Ghosh et al., 
2006) 
Lipotechoic acid from 
S. aureus (LTA) 
TLR2 10 μg/ml RAW264.7 Increased 
expression of 
IL-1b, TNF-α, 
IL-6, and IP-10 
(Paulnock et 
al., 2000) 
Lipopolysaccharide 
from P. gingivalis (PG-
LPS) 
TLR2 0.1 μg/ml U373  Secretion of IL-
6 
(Yoshimura 
et al., 2002) 
FSL-1  
(synthetic) 
TLR2 0.1 μg/ml PBMC Induction of 
Type I and 
Type II IFN 
(Ghosh et al., 
2006) 
Poly (I:C) (synthetic) TLR3 10 μg/ml PBMC Production of 
IL-8, MCP-1, 
and TNF-α 
(Uehara et 
al., 2007) 
E. coli K12 
lipopolysaccharide 
(LPS) 
TLR4 0.01, 0.1, and 1 
μg/ml 
PBMC Production of 
TNF-α, IL-6, 
and IL-10 
(Bekeredjian-
Ding et al., 
2006; Wang 
et al., 2000) 
S. typhimurium 
flagellin 
TLR5 0.1 μg/ml PBMC Activation of 
NF-κB 
(Zeng et al., 
2006) 
Imiquimod (IMIQ) 
(synthetic) 
TLR7 3 μg/ml PBMC Expression of 
IFN, TNF-α, IL-
6, and IL-8 
increased 
(Megyeri et 
al., 1995) 
Gardiquimod (GIMIQ) 
(synthetic) 
TLR7 1 μg/ml Plasmacytoid 
dendritic cells 
Expression of 
IFN-α, IFN-β, 
and RANTES 
increased 
(Phipps-
Yonas et al., 
2008) 
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Loxoribine 
(synthetic) 
TLR7 0.2 mM RAW264.7 
mouse 
macrophage 
cell line  
NK cells  
Expression of 
IL-23 p19 
increased 
Activation of 
NK cells 
(Al-Salleeh 
and Petro, 
2007; Pope 
et al., 1993) 
ssRNA40  
(synthetic) 
TLR8 1 μg/ml Peripheral 
blood 
Activation of 
TNF-α 
(Levy et al., 
2006) 
E. coli ssDNA/LyoVec TLR9 0.3-10 μg/ml RAW264.7 Production of 
nitrite 
(Roberts et 
al., 2005) 
ODN2006 
(synthetic) 
TLR9 2 μM PBMC Increased 
production of 
IFN-γ, IFN-α, 
IL-6, IL-8, and 
IL-12 
(Bauer et al., 
1999; Bauer 
et al., 2001) 
ODN2216 
(synthetic) 
TLR-9 1 μM Plasmacytoid 
dendritic  
cells  
Decreased 
production of 
IFN-α 
(Kwok et al., 
2008) 
Peptidoglycan from S. 
aureus (PGN) 
NLR 0.1-10 μg/ml HEK-293 Activation of 
NF-κB 
(Mitsuzawa 
et al., 2001) 
 
aThis table summarizes the concentration of agonists used by other workers. TLR, Toll-like 
receptor; PBMC, human peripheral blood mononuclear cells; IL, interleukin; IFN, interferon; TNF, 
tumor necrosis factor; NF-κB, nuclear factor-κB; HEK-293, human embryonic kidney-293 cells; 
PGN, peptidoglycan. 
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Figure 2.3.1:  Toll-like receptor 3 (TLR3) and TLR7 agonists do not affect 
fibrocyte differentiation. Human peripheral blood mononuclear cells (PBMCs) 
were cultured in different concentrations of the TLR3 agonist polyinosine-
polycytidylic acid (Poly I:C) and the TLR7 agonists imiquimod (IMIQ), 
gardiquimod (GIMIQ) and loxoribine. After 5 days, the cells were air-dried, fixed 
and stained, and the number of fibrocytes was counted. The results are means ± 
SEM of fibrocytes per 2.5 × 105 PBMCs (n = 3 separate experiments). Although 
high concentrations of IMIQ and GIMIQ appear to decrease the number of 
fibrocytes compared to no addition, the decrease is not significant by either 
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analysis of variance (ANOVA) or t-test. Arrows indicate the reported 
concentrations for the TLR agonists previously shown to be functional (Table 
2.3.1). 
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Figure 2.3.2 TLR8 and TLR9 agonists do not affect fibrocyte differentiation. 
Human PBMCs were cultured in different concentrations of the TLR8 agonist 
single-stranded RNA40 (ssRNA40) and the TLR9 agonists Escherichia coli 
ssDNA, ODN2006 and ODN2216. ODN2006 and ODN2216 are synthetic 
oligonucleotides that contain CpG dinucleotides at specific sequences. The 
controls for these oligonucleotides are ODN2006 control and ODN2216 control, 
which contain GpC dinucleotides instead of CpG dinucleotides. After 5 days, the 
cells were air-dried, fixed and stained, and the number of fibrocytes was counted. 
The results are means ± SEM of fibrocytes per 2.5 × 105 PBMCs (n = 3 separate 
experiments). Although high concentrations of E. coli ssDNA appear to decrease 
the number of fibrocytes compared to no addition, the decrease is not significant 
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by either ANOVA or t-test. High concentrations of ODN2216 and ODN2216 
control appear to increase fibrocyte number compared to no addition, but the 
increase is not significant by either ANOVA or t-test. Arrows indicate the 
concentrations of TLR agonists used by other workers (Table 2.3.1). 
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Figure 2.3.3 TLR agonists affect PBMCs. (A). Human PBMCs were cultured in 
the absence (serum-free medium (SFM) control) or the presence of 0.89 μg/ml 
TLR2 agonists Pam3CSK4, 8.9 × 107 cells/ml heat-killed Listeria monocytogenes 
(HKLM), 1.79 μg/ml lipotechoic acid (LTA), or 8.9 μg/ml lipopolysaccharides from 
Porphyromonas gingivalis (PG-LPS), 8.9 μg/ml TLR3 agonist Poly (I:C), 0.89 
μg/ml TLR4 agonist LPS, 0.89 μg/ml TLR5 agonist flagellin, 0.89 μg/ml TLR2/6 
agonist FSL-1, 0.89 μg/ml TLR7 agonist IMIQ, 0.89 μg/ml TLR8 agonist ssRNA, 
4.47 μM TLR9 agonist ODN 2006 or 1.79 μg/ml nucleotide oligomerization 
domain (NOD)-like receptor (NLR) agonist peptidoglycan (PGN). On day 3, the 
conditioned media were tested for the presence of tumor necrosis factor (TNF)-α 
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using enzyme-linked immunosorbent assay. The results are means ± SEM of 
TNF-α concentration (n = 3 or more separate experiments). (B) Human PBMCs 
were cultured in the presence or absence of Poly (I:C), IMIQ and PGN as 
described for Figure 2.3.3A. After 1 day, PBMCs were removed and stained for 
CD86 (n = 3 separate experiments). (C) Human PBMCs were cultured in the 
presence or absence of 8.9 μg/ml TLR3 agonist Poly (I:C), 0.89 μg/ml TLR7 
agonist IMIQ or 1.79 μg/ml NLR agonist PGN. On day 3, PBMCs were removed 
from the tissue culture plate and stained for major histocompatibility complex 
(MHC) class II. The results are means ± SEM of positive MHC class II cells (n = 4 
separate experiments). *P < 0.05 and **P < 0.01 compared to no-agonist control 
(SFM) according to t-test. 
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TLR4 recognizes bacterial LPSs, and TLR5 recognizes bacterial flagellin 
(Bekeredjian-Ding et al., 2006; Wang et al., 2000; Zeng et al., 2006). We 
observed that 0.89 μg/ml LPS or 0.89 μg/ml flagellin had no effect on fibrocyte 
differentiation (Figure 2.3.4). Although the number of fibrocytes decreased in 
PBMCs treated with LPS or flagellin, t-tests showed no significant difference 
compared to no TLR agonist. Both LPS and flagellin caused PBMCs to increase 
their accumulation of extracellular TNF-α (Figure 2.3.3A), which suggests that the 
LPS and flagellin we used have biological effects on PBMCs. Together, the data 
suggest that TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 agonists do not 
significantly affect the in vitro differentiation of human fibrocytes. 
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Figure 2.3.4. TLR4 and TLR5 agonists do not affect fibrocyte differentiation. 
Human PBMCs were cultured in the presence or absence of 0.89 μg/ml TLR4 
agonist LPS or 0.89 μg/ml TLR5 agonist flagellin. After 5 days, the cells were air-
dried, fixed and stained, and the number of fibrocytes was counted. The results 
are means ± SEM of fibrocytes per 2.5 × 105 PBMCs (n = 6 separate 
experiments). Although LPS and flagellin appear to decrease the number of 
fibrocytes compared to no addition, the decrease is not significant by either 
ANOVA or t-test.  
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2.3.2 TLR2 agonists inhibit the differentiation of PBMCs to fibrocytes 
TLR2 receptors recognize bacterial lipoproteins and lipotechoic acid from 
bacterial membranes, and they mediate the activation of transcription factors 
such as NF-κB and IFN-regulatory factors (Gallucci and Matzinger, 2001; Iwasaki 
and Medzhitov, 2004; Janeway and Medzhitov, 1999; Trinchieri and Sher, 2007). 
We found that at concentrations similar to those used in other studies (Table 
2.3.1), all six TLR2 agonists tested inhibited fibrocyte differentiation (Figure 
2.3.5). At day 5, the TLR2 agonist-treated cells appeared to be viable as 
determined by phase contrast microscopy (Figure 2.3.6). At day 5 after TLR2 
agonist treatment, there was no significant difference in the number of viable 
PBMCs treated with or without TLR2 agonists (Figure 2.3.6B). 
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Figure 2.3.5. TLR2 agonists inhibit fibrocyte differentiation. Human PBMCs were 
cultured in different concentrations of the TLR2 agonists Pam3CSK4, HKLM, 
lipomannans from Mycobacterium smegmatis (LM-MS), LTA, PG-LPS and FSL-
1. After 5 days, the cells were air-dried, fixed and stained, and the number of 
fibrocytes was counted. The results are means ± SEM of fibrocytes per 2.5 × 105 
PBMCs (n = 6 separate experiments for Pam3CSK4 and n = 3 separate 
experiments for the rest of the TLR2 agonists). The absence of error bars 
indicates that the error was smaller than the plot symbol. Statistical significance 
was analyzed by ANOVA using Dunnettʼs test to compare values against the no-
agonist control for all the agonists except LM-MS, which was analyzed by t-test. 
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*P < 0.05, **P < 0.01, and ***P < 0.001 compared to no-agonist control. Arrows 
indicate the concentration of TLR2 agonists used by other workers (Table 2.3.1). 
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Figure 2.3.6. Human PBMCs cultured in the presence of TLR2 agonists are 
viable. Human PBMCs were cultured in the (A) absence or (B) presence of 1.79 
μg/ml TLR2 agonist LTA or (C) 0.89 μg/ml TLR7 agonist IMIQ. After 5 days, the 
cells cultured in different conditions were photographed. Bar is 20 μm. (D) 
Human PBMCs were cultured in the absence (SFM control) or presence of 0.89 
μg/ml TLR2 agonists Pam3CSK4, 8.9 × 107 cells/ml HKLM, 0.89 μg/ml LM-MS, 
1.79 μg/ml LTA, 8.9 μg/ml PG-LPS or 0.89 μg/ml FSL-1 for 5 days. After 5 days, 
the cells were photographed and the number of cells per picture was counted. 
The results are means ± SEM of cells per 0.15 mm2 (n = 3 separate 
experiments). 
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Besides TLRs, there are also other pattern recognition receptors (PRRs) 
present in PBMCs that detect a variety of microbial molecules, including NLRs, 
that contain a NOD- and ligand-recognizing leucine-rich repeat (Philpott and 
Girardin, 2004). NLRs are intracellular receptors that recognize a variety of 
microbial molecules. We investigated the role of PGN on fibrocyte differentiation, 
since this agonist appears to be a NLR agonist (Travassos et al., 2004). When 
added to PBMCs, PGN at concentrations from 0.01 to 6.7 μg/ml did not affect 
fibrocyte differentiation (Figure 2.3.7). Although not statistically significant, PGN 
increased the number of CD86- and MHC class II-positive cells (Figures 2.3.3B 
and 2.3.3C). Together, the data suggest that although PGN has no effect on 
fibrocyte differentiation when added to PBMCs, it still has some effect on cells. 
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Figure 2.3.7. The NLR agonist PGN does not affect fibrocyte differentiation. 
Human PBMCs were cultured in different concentrations of PGN. After 5 days, 
the cells were air-dried, fixed and stained, and the number of fibrocytes was 
counted. The results are means ± SEM of fibrocytes per 2.5 × 105 PBMCs (n = 3 
separate experiments). There was no statistically significant difference between 
the effect of any PGN concentration and control, according to ANOVA or t-test. 
Arrows indicate the concentrations of PGN used by other workers (Table 2.3.1). 
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2.3.3 Some TLR2 agonists inhibit fibrocyte differentiation indirectly 
To determine whether TLR2 agonists act directly on human monocytes, 
we examined the effect of TLR2 agonists on purified monocytes. When TLR2 
agonists were added to purified human monocytes, the TLR2 agonists did not 
inhibit the differentiation of monocytes to fibrocytes (Figure 2.3.8). This suggests 
that TLR2 agonists do not inhibit fibrocyte differentiation by acting directly on 
monocytes. Interestingly, the NLR agonist PGN potentiated the differentiation of 
monocytes to fibrocytes (Figure 2.3.8). Since PGN had little activity when added 
to PBMCs (Figure 2.3.7), PGN might act directly on monocytes to potentiate 
fibrocyte differentiation and this activity might be inhibited by the presence of the 
other cells in the PBMC population. TLR4 agonist LPS also potentiated the 
differentiation of monocytes to fibrocytes (Figure 2.3.8), though the increase was 
not significant by either ANOVA or t-test. 
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Figure 2.3.8. TLR2 agonists do not inhibit the differentiation of purified 
monocytes to fibrocytes. Human monocytes were cultured in SFM for 5 days in 
the presence of LPS (1 μg/ml), PGN (2 μg/ml), Pam3CSK4 (1 μg/ml), HKLM (1 x 
108 cells/ml), LM-MS (1 μg/ml), PG-LPS (10 μg/ml), LTA (2 μg/ml) and FSL-1 (1 
μg/ml). The results are means ± SEM of fibrocytes per 2.5 × 105 PBMCs (n = 4 
separate experiments). *P < 0.05 compared to control (one-way ANOVA, 
Dunnettʼs test). 
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Since TLR2 agonists do not act directly on monocytes, a possible 
explanation for the ability of TLR2 agonists to inhibit fibrocyte differentiation when 
added to PBMCs is that the TLR2 agonists cause some cells in the PBMC 
population, such as T, B or NK cells, to secrete a factor that inhibits the 
differentiation of monocytes to fibrocytes. To test this possibility, we incubated 
PBMCs for 3 days with TLR2 agonists, collected the conditioned media and then 
added this to monocytes from the same donor. As previously observed, when 
added to PBMCs, TLR2 agonists inhibited the differentiation of fibrocytes (Figure 
2.3.9A). Conditioned media from PBMCs incubated with the TLR2 agonists 
lipomannans from Mycobacterium smegmatis (LM-MS), LPS from 
Porphyromonas gingivalis (PG-LPS) and LTA for 3 days inhibited the 
differentiation of monocytes to fibrocytes (Figure 2.3.9B). This suggests that 
these TLR2 agonists cause some nonmonocyte cells in the PBMC population to 
increase the accumulation of fibrocyte-inhibiting factors or to decrease the 
accumulation of fibrocyte-promoting factors in the extracellular medium. 
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Figure 2.3.9. Conditioned media from PBMCs incubated with LM-MS, PG-LPS 
and LTA inhibit fibrocyte differentiation. (A) Human PBMCs were cultured for 5 
days in the presence of the TLR2 agonists Pam3CSK4, HKLM, LM-MS, PG-LPS, 
LTA and FSL-1, the TLR4 agonist LPS, and the NLR agonist PGN, using the 
same concentrations as in Figure 2.3.6. SFM was used as a buffer control, and 
LPS and PGN were used as negative controls, since these agonists do not inhibit 
fibrocyte differentiation. Conditioned media were removed on day 3 from 
duplicates of these wells. The results are means ± SEM of fibrocytes per 2.5 × 
105 PBMCs (n = 5 separate experiments). *P < 0.05, **P < 0.01, and ***P < 0.001 
compared to control (one-way ANOVA, Dunnettʼs test). (B) Human monocytes 
were cultured for 5 days in the presence of the conditioned media from day 3 
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PBMCs incubated with TLR2 agonists. The results are means ± SEM of 
fibrocytes per 2.5 × 105 PBMCs (n = 5 separate experiments). Conditioned media 
from PBMCs incubated with the TLR2 agonists LM-MS, PG-LPS and LTA 
significantly inhibited the differentiation of monocytes to fibrocytes. *P < 0.05 
compared to control (one-way ANOVA, Dunnettʼs test).  
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2.3.4 Some TLR2 agonists cause PBMCs to secrete an unknown factor that 
inhibits fibrocyte differentiation  
We previously found that 1 ng/ml or more IFN-γ, 0.5 μg/ml or more SAP or 
10 μg/ml or more aggregated IgG directly inhibits monocytes from differentiating 
into fibrocytes and that 1 ng/ml or more IL-12 indirectly inhibits fibrocyte 
differentiation ((Pilling et al., 2003; Pilling et al., 2006; Shao et al., 2008). In 
cultures of PBMCs containing fetal bovine serum, IFN-α inhibits fibrocyte 
differentiation (Wang et al., 2007a). In our serum-free culture system, 0.1 ng/ml 
or more IFN-α also inhibited fibrocyte differentiation (Figure 2.3.10). To determine 
whether one of these inhibitory factors is the antifibrocyte factor present in 
conditioned media from PBMCs incubated with the TLR2 agonists LM-MS, PG-
LPS and LTA, we examined the levels of IFN-α, IFN-γ, IL-12, SAP and IgG in the 
conditioned media. Conditioned media from PBMCs incubated with TLR2 
agonists as well as the TLR4 agonist LPS did not show any detectable levels of 
IL-12 or SAP, with a detection limit of 0.1 ng/ml for both factors (data not shown). 
These conditioned media also had less than 0.01 ng/ml IFN-γ (Table 2.3.2 and 
data not shown). The conditioned media also did not show any detectable levels 
of either IFN-α or IgG, with a detection limit of 1 pg/ml IFN-α and 1 μg/ml IgG 
(data not shown). We further analyzed day 3 conditioned media from PBMCs 
incubated with Pam3CSK4, PG-LPS, LTA, PGN and LPS for the presence of 
Th1/Th2/Th17 cytokines. There were no detectable levels of IL-2, IL-4, IL-5, IL-
10, IL-12, IL-13 or IL-17A with a detection level of approximately 15 pg/ml for 
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each of the cytokines. We detected IL-6, TNF-α, IFN-γ, G-CSF and TGF-β1 in 
conditioned media from LTA (TLR2 agonist)-treated PBMCs, LPS (TLR4 
agonist)-treated PBMCs, and control PBMCs (Table 2.3.2). We then analyzed the 
effect of cocktails of these five cytokines on fibrocyte differentiation. Cytokine 
cocktails corresponding to the amount of the five cytokines found in LTA-treated 
conditioned media, LPS-treated conditioned media or control conditioned media 
did not have any significant effect on fibrocyte differentiation (Figure 2.3.11). In 
addition, cocktails containing higher levels of the five cytokines had no significant 
effect on fibrocyte differentiation (Figure 2.3.11). These observations indicate that 
the LTA-induced factor in the PBMC conditioned media that inhibits fibrocyte 
differentiation is not one of the five cytokines that we found in LTA-treated 
conditioned media and thus appears to be a novel factor. 
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Figure 2.3.10. Interferon (IFN)-α inhibits fibrocyte differentiation. Human PBMCs 
were cultured in different concentrations of IFN-α. After 5 days, the cells were air-
dried, fixed and stained, and the number of fibrocytes was counted. The results 
are means ± SEM of fibrocytes per 2.5 × 105 PBMCs (n = 3 separate 
experiments). *P < 0.05 and **P < 0.01 compared to no IFN-α control (one-way 
ANOVA, Dunnettʼs test). 
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Table 2.3.2 Conditioned media from LTA-treated PBMC, LPS-treated PBMC, 
and control conditioned media contain low levels of IL-6, TNF-α, IFN-γ , G-
CSF and TGF-β1* 
 
 
Cytokine 
Concentration in 
control CM (pg/ml) 
Concentration in LPS-
treated CM (pg/ml) 
Concentration in LTA-
treated CM (pg/ml) 
IL-6 4 ± 12 530 ± 250 750 ± 250 
TNF-α 4.6 ± 1.6 29 ± 13 33 ± 6 
IFN-γ 1.0 ± 0.5 2.4 ± 0.9 4.5 ± 3.5 
G-CSF 2.5 ± 0 17 ± 0 9.3 ± 1.8 
TGF-β1 13 ± 1.8 3.5 ± 0 4.5 ± 0 
 
*The above five cytokines were detected in conditioned media (CM) from LTA-treated PBMCs, 
LPS-treated PBMCs and control PBMCs. This assay measures total transforming growth factor 
(TGF)-β1 as opposed to active TGF-β1. The results are means ± SEM of cytokine concentration 
(n = 2 separate experiments). 
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Figure 2.3.11. Cytokine mixtures from SFM, LTA or LPS conditioned media had 
no effect on fibrocyte differentiation. Human PBMCs were cultured in the 
absence of added cytokines (control) or in mixtures of cytokines (IL-6, TNF-α, 
granulocyte colony-stimulating factor (G-CSF), transforming growth factor (TGF)-
β1, and IFN-γ) at the concentrations found in conditioned media from SFM-, LTA-
, or LPS-treated PBMCs. Human PBMCs were also cultured in the presence of 
mixtures containing 1000 pg/ml, 500 pg/ml, 100 pg/ml, or 10 pg/ml of each of the 
five cytokines. After 5 days, the cells were dried, fixed and stained, and the 
number of fibrocytes was counted. The results are means ± SEM of fibrocytes 
per 2.5 × 105 PBMCs. (A) Results from one donor. (B) Results from a second 
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donor. For each donor, there was no significant difference between any cytokine 
mixture and the control (1-way ANOVA, Dunnettʼs test and t-test). 
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2.4 Discussion 
We found that a variety of TLR2 agonists inhibit fibrocyte differentiation. 
However, the TLR2 agonists do not directly inhibit the differentiation of 
monocytes to fibrocytes, but rather cause some other cell type in the PBMC 
population to inhibit monocytes from differentiating into fibrocytes. There are five 
known factors (IFN-α, IFN-γ,  IL-12, SAP and aggregated IgG) which inhibit 
fibrocyte differentiation (Pilling et al., 2003; Pilling et al., 2006; Shao et al., 2008; 
Wang et al., 2007a). Our data suggest that PBMCs incubated with some TLR2 
agonists secrete an unknown sixth factor that inhibits fibrocyte differentiation. 
 
 The TLR2 agonist LTA induces PBMCs to increase the extracellular 
accumulation of IL-6, TNF-α, IFN-γ and G-CSF and to decrease the extracellular 
accumulation of TGF-β1. Both TLR2 agonists and TLR4 agonist induce primary 
adrenocortical cells to secrete IL-6 (Kanczkowski et al., 2009; Taylor et al., 2006). 
However, we previously found that IL-6 has no effect on fibrocyte differentiation 
(Shao et al., 2008).  Like the above five factors, this combination of cytokines at 
the concentrations found in the conditioned media, or at higher concentrations, 
was unable to inhibit fibrocyte differentiation and is thus not the factor in LTA-
stimulated conditioned medium that inhibits fibrocyte differentiation. 
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 Monocytes express TLR1-TLR9, but not TLR10 (Hornung et al., 2002; 
Zarember and Godowski, 2002). They have a high expression of TLR1, TLR2 
and TLR4; intermediate expression of TLR 5, TLR6 and TLR8; and low 
expression of TLR7 and TLR9 (Hornung et al., 2002; Zarember and Godowski, 
2002). Once activated, TLR agonists trigger downstream signaling events by one 
of four adaptor molecules: MyD88, MyD88-like adaptor protein (Mal), 
Toll/Interleukin-1 receptor domain-containing adaptor protein-inducing IFN-β or 
TRIF-related adaptor molecule (TRAM) (Akira, 2006; Farhat et al., 2008; Hoebe 
et al., 2004; Keating et al., 2007). MyD88 activates mitogen-activated protein 
kinases (MAPKs) through IL-1R-associated kinase (MAPKs) and tumor necrosis 
factor receptor (TNFR)-associated factor 6 (TRAF-6) (Akira, 2006; Farhat et al., 
2008). The signaling eventually causes the translocation of transcription factors 
such as NF-κB and activator protein 1 (AP-1), which then induces the production 
of inflammatory cytokines such as TNF-α, IL-6, IL-1β and IL-12 (Farhat et al., 
2008). TLR3 does not require the MyD88 pathway; instead it induces the 
production of IFN-β via TRIF (Farhat et al., 2008; Yamamoto et al., 2003). TLR4 
can cause NF-κB activation by either a MyD88-dependent pathway or a MyD88-
independent pathway (Keating et al., 2007). TLR4 activates a MyD88-
independent pathway via TRIF, which complexes with TRAM and leads to NF-κB 
activation (Keating et al., 2007). Since none of the TLR agonists appeared to 
directly inhibit the differentiation of monocytes to fibrocytes, our data suggest that 
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none of the above signal transduction pathways in monocytes affects their ability 
to differentiate into fibrocytes. 
 
 TLR2 recognizes various bacterial components such as bacterial 
lipoproteins and LTA (Farhat et al., 2008; Gerold et al., 2008). PBMCs incubated 
with the TLR2 agonists LM-MS, PG-LPS and LTA secrete an unknown factor that 
inhibits fibrocyte differentiation. However, for unknown reasons, the TLR2 
agonists Pam3CSK4 (a synthetic triacylated lipopeptide), heat-killed Listeria 
monocytogenes (HKLM) and FSL-1 (a synthetic lipoprotein) do not appear to 
cause other cells in the PBMC population to secrete factors that inhibit fibrocyte 
differentiation. This suggests that these agonists indirectly inhibit fibrocyte 
differentiation by either cell-cell contact or a labile secreted factor. 
 
 We previously found that aggregated IgG inhibits fibrocyte differentiation 
(Pilling et al., 2006). We hypothesized that since aggregated IgG (that is, IgG 
bound to something such as a bacterium) signifies the presence of bacterial 
infection, and since closing an infected wound and thus forming an anaerobic 
pocket can be detrimental, the inhibition of fibrocyte differentiation by aggregated 
IgG might have evolved to prevent closure of septic wounds by fibrocytes. An 
interesting possibility is that the indirect inhibition of fibrocyte differentiation by 
TLR2 agonists allows other cells in a wound environment to check for the 
presence of bacteria, and if bacteria are present, to relay this information to 
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monocytes and prevent fibrocyte differentiation and the possible closure of an 
infected wound. 
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Chapter 3: High and low molecular weight hyaluronic acid differentially 
regulate human fibrocyte differentiation 
 
3.1 Introduction 
During tissue injury, the extracellular matrix component hyaluronic acid 
(HA) breaks down into smaller fragments (Jiang et al., 2007; Li et al., 2011; 
McKee et al., 1996).  HA is a negatively charged linear polymer of repeating units 
of (β,1-4)-D-glucuronic acid-(β,1-3)-N-acetyl-D-glucosamine that gives 
mechanical strength to tissues (Laurent and Fraser, 1992).  High molecular 
weight hyaluronic acid (HMWHA) has a molecular mass > 1 x 106 Da and is 
found in normal healthy tissue (Teder et al., 2002).  The concentration of 
hyaluronic acid is 15-150 μg/g in lung tissue, 200 μg/g in the vitreous humor of 
the eye, 500 μg/g in skin, and 1400-3600 μg/g in synovial fluid (Kuo, 2005).  In 
injured tissue, HMWHA breaks down to low molecular weight HA (LMWHA) 
(Jiang et al., 2007).  LMWHA masses range from 0.8 to 8 x 105 Da (Jiang et al., 
2007).  However, there are variations in the use of the terms HMWHA or 
LMWHA.  HMWHA often refers to any hyaluronic acid that has not been 
degraded (Filion and Phillips, 2001), therefore, in this chapter, I will use HMWHA 
for hyaluronic acid that is greater than 1 x 106 Da, LMWHA for 0.8 to 8 x 105 Da 
hyaluronic acid, and oligo-HA for < 6 x 103 Da hyaluronic acid.  Cells appear to 
be able to sense the difference between HMWHA, LMWHA, and oligo-HA 
(Bollyky et al., 2007; Chang et al., 2007; Day and de la Motte, 2005; McKee et 
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al., 1996; Nakamura et al., 2004; Scheibner et al., 2006; Termeer et al., 2002; 
Termeer et al., 2000).  For instance, LMWHA but not HMWHA stimulates alveolar 
macrophages to secrete inflammatory cytokines such as IL-8 (McKee et al., 
1996), while the maturation and activation of monocyte-derived dendritic cells is 
promoted by 1.2 x 103 Da HA, but not HMWHA or LMWHA (Termeer et al., 
2000).  
 
One of the major receptors that monocytes and lymphocytes express to 
detect HA is CD44 (Jiang et al., 2005; Jiang et al., 2007; Peach et al., 1993; 
Teder et al., 2002).  During lung injury, CD44 is used to clear degraded HA 
(McKee et al., 1996; Taylor et al., 2007b; Teder et al., 2002).  HA-CD44 
interactions help the movement of migratory cells during development and help 
the migration of immune cells into injured sites (Jiang et al., 2007; Laurent and 
Fraser, 1992; Siegelman et al., 1999).  HA-CD44 interactions also promote the 
adhesion and motility of fibroblasts, thus facilitating tissue repair and remodeling 
of the injured sites (Svee et al., 1996).  Monocytes, dendritic cells, and 
lymphocytes also bind HA using Toll-like receptors (TLR) such as TLR2 and 
TLR4 (Scheibner et al., 2006; Termeer et al., 2002).  LMWHA binds to either 
TLR2 or TLR4 to elicit pro-inflammatory action, while HMWHA dampens 
inflammation by inhibiting TLR2 or TLR4 signaling (Campo et al., 2010; 
Scheibner et al., 2006).  HA can also bind CD168 (receptor for hyaluronan-
mediated motility, RHAMM), a cell-surface receptor on fibroblasts and 
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macrophages (Zaman et al., 2005).  RHAMM is upregulated during inflammation 
and cancer (Hamilton et al., 2007; Zaman et al., 2005).  Finally, HA can also bind 
lymphatic vessel endothelial HA receptor (LYVE), which is found predominately 
in lymphatic endothelial cells and appears to clear HA from lymph (Johnson et 
al., 2007).  
 
Since LMWHA increases during tissue injury (Jiang et al., 2007), in this 
chapter I examined the effect of hyaluronic acid on fibrocyte differentiation.  I 
found that HMWHA promotes fibrocyte differentiation, while LMWHA inhibits 
fibrocyte differentiation.  
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3.2 Methods 
3.2.1 Culturing PBMC with hyaluronic acid, cytokines, SAP, and antibodies 
Peripheral blood mononuclear cells (PBMC) were isolated and incubated in 
RPMI-based serum free media (SFM) as described in chapter 2.2.1.  High 
molecular weight hyaluronic acid from rooster comb (HMWHA) and low molecular 
weight hyaluronic acid from umbilical cord (LMWHA) (both from Sigma-Aldrich, 
St. Louis, MO) were reconstituted to 25 mg/ml in water.  1,230 Da oligo-HA 
(Hyalose, Oklahoma City, OK) was reconstituted to 10 mg/ml in water.  All 
experiments were performed with at least three different batches of hyaluronic 
acid.  In some experiments, human serum amyloid P   (EMD Biosciences, San 
Diego, CA), recombinant human IL-4 (Peprotech, Rockhill, NJ), or recombinant 
human IL-13 (Peprotech) was also added to the cells.  Before use, SAP was 
buffer-exchanged as described previously (Shao et al., 2008).  To ligate surface 
receptors, PBMC were cultured in SFM with 2 μg/ml anti-human CD44 (clone 
G44-26) (BD Biosciences, San Jose, CA), anti-human CD44 (clone 515, an 
antibody that prevents HA binding to CD44) (Kansas et al., 1989; Siegelman et 
al., 1999) (BD Biosciences), anti-human CD43 (BD Biosciences), or mouse IgG1 
isotype control (BD Biosciences).  Dilutions of hyaluronic acid (or an equivalent 
volume of water as a control) were made in SFM.  Cells were cultured in 
duplicate wells of a 96 well tissue culture plate (BD Biosciences).  On day 5, 
fields of PBMC were photographed using a phase-contrast microscope with a 20 
x objective and viable cells counted as described previously (Maharjan et al., 
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2010).  Cells were then fixed, stained, and the number of fibrocytes was counted, 
as described previously (Maharjan et al., 2010; Pilling et al., 2003; Pilling et al., 
2006; Pilling et al., 2009; Shao et al., 2008).  Fibrocytes were identified as 
adherent spindle-shaped cells with an oval nucleus as described previously 
(Maharjan et al., 2010; Pilling et al., 2003; Pilling et al., 2006; Pilling et al., 2009).  
 
3.2.2 Treating hyaluronic acid with hyaluronidase  
3 mg/ml of HMWHA or 3 mg/ml of LMWHA in PBS were treated with 10 U/ml of 
hyaluronidase from Streptomyces hyalurolyticus (Sigma-Aldrich) for 1 or 4 hours 
at 37oC, and the digestion was stopped by boiling the solution for 5 minutes at 
100oC.  Electrophoresis of HA on agarose gels was done following (Lee and 
Cowman, 1994) with the exception that 10 μl of sample was mixed with 5 μl of 6 
x DNA loading buffer (Sharp et al., 1973), and 40 μl of 1 Kb DNA ladder (G5711, 
Promega, Madison, WI) was mixed with 10 μl of 6 x DNA loading buffer (Sharp et 
al., 1973).  15 μl of samples or DNA ladder were loaded on the gel, and this was 
run at 40 V for 8-10 hours (Lee and Cowman, 1994).  The gels were stained with 
0.005% Stains-All (Sigma-Aldrich) in 50% ethanol/water (Lee and Cowman, 
1994).  Dilutions of the digested hyaluronic acids (or PBS as a control) were 
made in SFM.   
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3.2.3 Detecting DNA, RNA, protein, or endotoxin contamination in HMWHA, 
LMWHA, or digested HMWHA 
1 μg/ml 1 Kb DNA ladder, 10 μg/ml, 1 μg/ml, or 0.1 μg/ml of HMWHA, LMWHA, 
or digested HMWHA were electrophoresed on 1% agarose gels containing 2 
μg/ml ethidium bromide for 2 hours at 40 V.  The gels were visualized by UV and 
photographed.  We also examined 10 ng/ml, 100 ng/ml, or 1000 ng/ml of 
HMWHA, or digested HMWHA at 260/280 nm on a Synergy MX (Biotek, 
Winooski, VT) microplate reader using a Take3 UV plate to examine the 
presence of DNA, RNA, or protein contamination, using BSA as a protein control.  
The detection limit of the Synergy MX is 2 ng/μl dsDNA, 2 ng/μl RNA, or 6 ng/μl 
protein.  We tested for the presence of endotoxin in digested HMWHA using 
THP-1 blue cells (Invivogen, San Diego, CA) and QuantiBlue (Invivogen) 
following the manufacturerʼs instructions.  
 
3.2.4 Preparation of monocytes 
CD16-negative monocytes were purified from 5 x 107 PBMC using an EasySep 
Monocyte Depletion Kit (StemCell Technology, Vancouver, Canada) following the 
manufacturerʼs instructions (Maharjan et al., 2010).  To determine the purity of 
the monocytes, cells were analyzed by flow cytometry (FACScan, BD 
Biosciences, or Accuri C6 flow cytometer, Ann Arbor, MI), as described 
previously (Maharjan et al., 2010; Pilling et al., 2009 ; Pilling et al., 2009; Shao et 
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al., 2008).  A sample of each monocyte preparation was stained with 5 μg/ml 
primary antibodies against CD3, CD14, CD16, CD19, and CD45, and then 
incubated with FITC-conjugated F(ab′)2 goat anti-mouse IgG antibodies (cross-
adsorbed against human Ig, Southern Biotechnology, Birmingham, AL, USA) as 
described previously (Maharjan et al., 2010; Shao et al., 2008).  Only negatively 
selected cells in excess of 98% pure were used, as determined by the positive 
expression of CD14 and CD45.  Less than 1% of the cells showed staining for 
the T cell marker CD3, the NK cell marker CD16, or the B cell marker CD19.  100 
μl of purified monocytes at 5 x 105 cells/ml in SFM was mixed with 100 μl of 600 
μg/ml HMWHA in SFM, 600 μg/ml LMWHA in SFM, or a water dilution control.  
On day 5, the cells were fixed, stained, and the number of fibrocytes was 
counted.    
 
3.2.5 Immunocytochemistry for fibrocytes 
PBMC were cultured on eight-well glass slides (Lab-Tek, Nalge Nunc 
International, Naperville, IL) in the presence or absence of 300 μg/ml HMWHA or 
SFM for 5 days, as described previously (Pilling et al., 2009 ).  Slides were then 
gently tilted to reduce dislodging cells and the media was then removed from the 
corner of the well. Immunocytochemistry was performed as described previously 
(Pilling et al., 2009 ) with antibodies against CD13 (BioLegend, San Diego, CA), 
CD14 (BioLegend), CD34 (BD Biosciences), CD45RO (BioLegend), CXCR4 
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(R&D Systems, Minneapolis, MN), and collagen I (Rockland Immunochemicals, 
Gilbertsville, PA).  
 
3.2.6 Immunofluorescence and staining for hyaluronic acid 
PBMC were cultured on eight-well glass slides (Lab-Tek, Nalge Nunc 
International, Naperville, IL) for 5 days, as described previously (Pilling et al., 
2009 ; Shao et al., 2008).  Slides were then gently tilted to reduce dislodging cells 
and the media was then removed from the corner of the well.  400 μl of TBS was 
then gently added to the wells and then gently pipetted out from the corner of the 
well.  The cells were then fixed with 200 μl of 2% paraformaldehyde (PFA) in 
PBS for 15 minutes at room temperature.  After the PFA was removed, 400 μl of 
ice-cold methanol was added to the wells for 1 hour at 4oC to permeabilize the 
cells.  After gently removing the methanol, 400 μl of TBS was added to the wells 
for 10 minutes at room temperature and then gently pipetted out from the corner 
of the well.  This was repeated twice.  400 μl of TBS containing 5% BSA (TBS-
5% BSA) was then added to the wells at room temperature for 60 minutes to 
reduce nonspecific binding.  These PBMC slides were then incubated with 5 
μg/ml mouse anti-human-CD44 (G44-26), rabbit anti-human-RHAMM (clone 
EPR4055 Epitomics, Burlingame, CA), or mouse IgG1, isotype control, at room 
temperature for 60 minutes.  Wells were washed with 400 μl of TBS, and then 
incubated with 2.5 μg/ml FITC-conjugated F(ab′)2 goat anti-mouse or goat anti-
rabbit IgG antibodies (Southern Biotechnology, Birmingham, AL) at room 
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temperature for 30 minutes.  After washing the slides with TBS, the slides were 
mounted with Vectashield mounting media containing DAPI (Vector Laboratories, 
Burlingame, CA).  Images of the cells were captured on an Axioplan2 microscope 
(Zeiss) with a CoolSNAP HQ digital camera (Photometrics, Tucson, AZ) and 
Metamorph software (Molecular Devices, Dowingtown, PA).  
 
To stain for hyaluronic acid, purified human monocytes were cultured in the 
presence or absence of 300 μg/ml HMWHA or LMWHA in eight-well glass slides 
as above for 30 minutes.  The media was gently pipetted out and cells were 
fixed, permeabilized, and non-specific binding reduced as above.  The 
monocytes were then incubated with biotinylated hyaluronic acid binding protein 
(bio-HABP) (Northstar Associates, East Falmouth, MA) diluted 1:500 in TBS-5% 
BSA at room temperature for 60 minutes.  Wells were washed with 400 μl of 
TBS, and then incubated with 1.0 μg/ml streptavidin-FITC (BD Biosciences) at 
room temperature for 30 minutes.  After washing the slides with TBS, the slides 
were mounted as above.   
 
3.2.7 Statistics 
Statistical analysis was performed using GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA).  Statistical significance was defined as p < 0.05 
as determined by the statistical methods indicated in the figure legends.  
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3.3 Results 
3.3.1 HMWHA potentiates fibrocyte differentiation whereas LMWHA inhibits 
fibrocyte differentiation 
Hyaluronic acid is a negatively charged glycosaminoglycan that is 
abundantly present in extracellular matrix (Girish and Kemparaju, 2007; Kuo, 
2005; Laurent and Fraser, 1992; Scheibner et al., 2006; Stern et al., 2006).  To 
investigate the role of hyaluronic acid on fibrocyte differentiation, PBMC were 
cultured in the presence of two different sizes of hyaluronic acid.  According to 
the manufacturer, HMWHA has a range of molecular masses with a peak at 2 x 
106 Da and LMWHA has a range of molecular masses with a peak at 7.5 x 105 
Da; as described below, these sizes were verified by gel electrophoresis.  In our 
serum-free culture media, when PBMC were incubated with HMWHA or LMWHA, 
we found that 300 μg/ml HMWHA potentiated fibrocyte differentiation, whereas 
300 μg/ml LMWHA inhibited fibrocyte differentiation (Figure 3.3.1).  These data 
suggest that HMWHA and LMWHA have opposite effects on fibrocyte 
differentiation. All batches of HMWHA and LMWHA were tested for protein, RNA, 
DNA, and these were found to be below the level of detection (data not shown). 
PBMC treated with 300 μg/ml, 100 μg/ml, 0.03 μg/ml, or 0.01 μg/ml HMWHA or 
LMWHA had no significant difference in the number of viable cells at 5 days 
compared to untreated cells (Figure 3.3.2).  These data suggest that HMWHA 
and LMWHA have opposite effects on fibrocyte differentiation without affecting 
total cell viability.   
  64 
 
Figure 3.3.1 High molecular weight hyaluronic acid (HMWHA) promotes fibrocyte 
differentiation, while low molecular weight hyaluronic acid (LMWHA) inhibits 
fibrocyte differentiation.  Human PBMC were cultured in the indicated 
concentrations of HMWHA and LMWHA.  After 5 days, the cells were air dried, 
fixed, stained, and the number of fibrocytes was counted.  Fibrocytes were 
identified as adherent spindle-shaped cells with an oval nucleus.  For each 
donor, values were calculated as the percent of the no-HA control.  The results 
are mean ± SEM (n = 6 separate experiments for HMWHA and n = 5 separate 
experiments for LMWHA).  The number of fibrocytes per 2.5 x 105 PBMC for the 
no-HA controls from the 6 donors was 808, 400, 296, 450, 850, and 1200.  * 
indicates p < 0.05 and ** p < 0.01, compared to control as determined by t-test. 
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Using the non-parametric Mann Whitney two-tailed t-test, 300 μg/ml and 100 
μg/ml HMWHA significantly increases the number of fibrocytes when compared 
to control with p < 0.001, and 300 μg/ml LMWHA significantly decreases the 
number of fibrocytes when compared to control with p < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  66 
 
Figure 3.3.2. HMWHA and LMWHA do not affect cell viability.  Human PBMC 
were cultured in the absence (SFM) or presence of the indicated concentrations 
of HMWHA or LMWHA for 5 days.  After 5 days, the number of cells was 
counted.  The results are mean ± SEM of viable cells per 0.15 mm2 (n = 4 
separate experiments).  There was no statistical significance as analyzed by 
ANOVA or t-test. 
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To confirm that the long spindle-shaped cells are fibrocytes, I stained day 
5 PBMC incubated with 300 μg/ml HMWHA or SFM for fibrocyte markers such as 
CD13, CD34, CD45RO, CXCR4, and collagen I.  When PBMC were cultured in 
the presence of 300 μg/ml HMWHA or SFM for 5 days, the long spindle-shaped 
cells stained positively for CD13, CD34, CD45RO, CXCR4, and collagen I (data 
not shown).  I also stained the day 5 PBMC cultured in 300 μg/ml HMWHA or 
SFM for the monocyte marker CD14 and the macrophage marker PM2K.  
Fibrocytes from both conditions did not stain for CD14 or PM2K (data not shown).  
There were few non-fibrocyte cells that stained positively for CD14 and PM2K 
(data not shown).  Together, these observations indicate that the long spindle-
shaped cells are fibrocytes.  
 
3.3.2 Hyaluronidase treated HA inhibits fibrocyte differentiation 
Since HMWHA potentiated fibrocyte differentiation and LMWHA inhibited 
fibrocyte differentiation, it is possible that HMWHA contains a contaminant that 
potentiates fibrocyte differentiation, or LMWHA contains a contaminant that 
inhibits fibrocyte differentiation.  To confirm that hyaluronic acid of different sizes 
have different effects, we digested HMWHA into smaller fragments with 
hyaluronidase to determine if digested HMWHA inhibits fibrocyte differentiation.  
HMWHA had a range of molecular mass of approximately 6.3 x 106 Da - 2 x 106 
Da (Figure 3.3.3A).  The size range of the HMWHA digested with hyaluronidase 
was equivalent to the size of LMWHA (a mass range of approximately 6 x 105 Da 
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- 8 x 105 Da) as analyzed by gel electrophoresis, while hyaluronidase treatment 
of LMWHA slightly decreased the upper end of the size range of the LMWHA 
(Figure 3.3.3A).  Hyaluronidase may have digested the HMWHA and LMWHA 
into smaller sizes such as oligo hyaluronic acid.  However, I was unable to detect 
these smaller sizes on the gel.  Hyaluronidase-treated HMWHA and LMWHA 
inhibited fibrocyte differentiation (Figure 3.3.3B).  Hyaluronidase-containing PBS 
had no effect on fibrocyte differentiation (data not shown).  Since HMWHA were 
digested with bacterial hyaluronidase, it is possible that the digested HMWHA 
may contain endotoxins that are actually causing the inhibition of fibrocyte 
differentiation.  Hyaluronidase digested HMWHA always had endotoxin below 
detectable levels (data not shown).  Treatment of PBMC with HMWHA and 
LMWHA digested with hyaluronidase also did not affect cell viability at 5 days 
(data not shown). Together, this suggests that the potentiation of fibrocyte 
differentiation by HMWHA and the inhibition of differentiation by LMWHA are not 
due to a non-HA contaminant.  
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Figure 3.3.3. HMWHA and LMWHA treated with hyaluronidase inhibit fibrocyte 
differentiation.  (A) HMWHA and LMWHA were treated with 10 U/ml of 
hyaluronidase for 1 and 4 hours at 37oC.  Samples were analyzed by agarose gel 
electrophoresis.  M, 1 Kb ladder; Lane 1, HMWHA; Lane 2, HMWHA incubated 
with hyaluronidase for 1 hour; Lane 3, HMWHA incubated with hyaluronidase for 
4 hours; Lane 4, LMWHA; Lane 5, LMWHA incubated with hyaluronidase for 1 
hour; Lane 6, LMWHA incubated with hyaluronidase for 4 hours; Lane 7, PBS; 
Lane 8, PBS incubated with hyaluronidase for 1 hour; and Lane 9, PBS incubated 
with hyaluronidase for 4 hours.  (B) Human PBMC were cultured in 300 μg/ml of 
4 hours-hyaluronidase-treated or untreated HMWHA and LMWHA.  After 5 days, 
the cells were air dried, fixed, stained, and the number of fibrocytes was counted.  
The results are mean ± SEM of SFM percent control (n = 6 separate 
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experiments).  The number of fibrocytes in SFM controls from the 6 donors was 
883, 1029, 808, 288, 400, and 288. * indicates p < 0.05, ** p < 0.01, *** p < 0.001 
as determined by t-test.  Using the non-parametric Mann Whitney two-tailed t-
test, 300 μg/ml HMWHA significantly increases the number of fibrocytes when 
compared to control with p < 0.001, but 300 μg/ml hyaluronidase incubated 
HMWHA is not significantly different from control.  Also, 300 μg/ml LMWHA 
significantly decreases the number of fibrocytes when compared to control with p 
< 0.001, and 300 μg/ml hyaluronidase incubated LMWHA also significantly 
decreases the number of fibrocytes when compared to control with p < 0.001.  
Using the non-parametric Mann Whitney one-tailed t-test, 300 μg/ml 
hyaluronidase incubated HMWHA significantly decreases the number of 
fibrocytes when compared to control with p < 0.05. 
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High and low molecular weight HA are present at sites of injury (Bollyky et 
al., 2007; Jiang et al., 2007; Powell and Horton, 2005).  I therefore examined how 
combinations of 300 μg/ml HMWHA and 300 μg/ml LMWHA affect fibrocyte 
differentiation.  The number of fibrocytes observed in PBMC treated with a 
combination of HMWHA and LMWHA was significantly lower compared to PBMC 
cultured with HMWHA alone, but not significantly different compared to PBMC 
cultured with LMWHA alone (Figure 3.3.4). In this experiment, I added 2.7 times 
more moles of LMWHA than HMWHA.  It is possible that the increased amount of 
LMWHA that I added neutralized the effect of HMWHA on fibrocyte 
differentiation.  When we analyze the data with Mann Whitney one-tailed t-tests, I 
observe that 300 μg/ml HMWHA or 300 μg/ml LMWHA are significantly different 
from the combination of 300 μg/ml HMWHA and LMWHA, which suggests that 
HMWHA and LMWHA both neutralize each otherʼs effect on fibrocyte 
differentiation.   
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Figure 3.3.4.  LMWHA inhibits HMWHA-induced fibrocyte differentiation.  Human 
PBMC were cultured in SFM (control), SFM with 300 μg/ml HMWHA, SFM with 
300 μg/ml LMWHA, or SFM with 300 μg/ml HMWHA and 300 μg/ml LMWHA.  
After 5 days, the cells were air dried, fixed, stained, and the number of fibrocytes 
was counted.  The results are mean ± SEM of percent of control (n = 3 separate 
experiments).  The number of fibrocytes per 2.5 x 105 PBMC in controls from the 
3 donors was 1525, 713, and 1290.  * indicates p < 0.05, ** p < 0.01, *** p < 
0.001 compared to control as determined by ANOVA.  Using the non-parametric 
Mann Whitney two-tailed t-test, there is no statistical significant difference among 
different experimental groups.  Using the non-parametric Mann Whitney one-
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tailed t-test, 300 μg/ml HMWHA significantly increases the number of fibrocytes 
when compared to control with p < 0.05, 300 μg/ml LMWHA significantly 
decreases the number of fibrocytes when compared to control with p < 0.05, 300 
μg/ml HMWHA and 300 μg/ml LMWHA significantly decreases the number of 
fibrocytes when compared to control with p < 0.05.  Additionally, 300 μg/ml 
HMWHA significantly increases the number of fibrocytes when compared to 300 
μg/ml LMWHA or the combination of 300 μg/ml HMWHA and LMWHA with p < 
0.05.  300 μg/ml LMWHA significantly decreases the number of fibrocytes when 
compared to 300 μg/ml HMWHA or the combination of 300 μg/ml HMWHA and 
LMWHA with p < 0.05. 
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3.3.3 HMWHA and LMWHA directly affect the differentiation of monocytes to 
fibrocytes 
We previously found that IL-12 and TLR2 agonists, when added to a 
population of PBMC, indirectly affect monocyte to fibrocyte differentiation 
(Maharjan et al., 2010; Shao et al., 2008), while factors such as SAP, IL-4, IL-13, 
or aggregated IgG directly affect monocyte to fibrocyte differentiation (Pilling et 
al., 2003; Pilling et al., 2006; Shao et al., 2008). Therefore, I examined whether 
HMWHA or LMWHA act directly on human monocytes.  When 300 μg/ml 
HMWHA or LMWHA were added to purified monocytes, HMWHA potentiated 
fibrocyte differentiation while LMWHA inhibited fibrocyte differentiation (Figure 
3.3.5).  This suggests that HMWHA and LMWHA act directly on monocytes to 
either potentiate or inhibit fibrocyte differentiation.    
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Figure 3.3.5.  HMWHA potentiates but LMWHA inhibits the differentiation of 
purified monocytes to fibrocytes.  Purified human monocytes were cultured in 300 
μg/ml of either HMWHA or LMWHA for 5 days.  After 5 days, the cells were air 
dried, fixed, stained, and the number of fibrocytes was counted.  The results are 
mean ± SEM of percent no-HA control (n = 3 separate experiments).  The 
number of fibrocytes per 2.5 x 105 monocytes in controls from the 3 donors was 
4250, 2450, and 1600.  * indicates p < 0.05 and ** indicates p < 0.01 compared 
to control as determined by t-test.  Using the non-parametric Mann Whitney two-
tailed t-test, there is no significant difference among the control, 300 μg/ml 
HMWHA, or 300 μg/ml LMWHA. Using the non-parametric Mann Whitney one-
tailed t-test, 300 μg/ml HMWHA significantly increases the number of fibrocytes 
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when compared to control, 300 μg/ml LMHWA significantly decreases the 
number of fibrocytes when compared to control. 
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3.3.4 The pro-fibrocyte effect of HMWHA varies with different cell density 
 
 Since HMWHA and LMWHA directly affect the differentiation of monocytes 
to fibrocytes, it is possible that HMWHA potentiates the number of fibrocytes 
while LMWHA inhibits the number of fibrocytes because HMWHA can cause cell-
cell interactions due to its large size.  An alternative hypothesis is that HMWHA 
potentiates fibrocyte differentiation because it has more PBMC binding sites due 
to its length.  To test these hypotheses, I incubated PBMCs with HMWHA at 
three different cell densities.  At 0.125 x 106 cells/ml PBMC, HMWHA potentiated 
fibrocyte differentiation more than 0.5 x 106 cells/ml or 2.0 x 106 cells/ml (Figure 
3.3.6).  At 2.0 x 106 cells/ml, PBMCs clumped together and probably interfered 
with fibrocyte differentiation.  HMWHA potentiated more fibrocytes in 0.125 x 106 
cells/ml than in 0.5 x 106 cells/ml cultures, which suggests that the potentiation of 
fibrocyte differentiation by HMWHA is not due to cell-cell interactions due to the 
large size of HMWHA.  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Figure 3.3.6: The pro-fibrocyte effect of HMWHA varies with different cell density.  
Human PBMC at different cell densities were cultured in serum-free medium for 5 
days in the presence of 300 μg/ml HMWHA. The results are mean ± SEM of 
fibrocytes (n = 3 separate experiments).  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3.3.5 Oligo hyaluronic acid has no effect on fibrocyte differentiation.  
Since LMWHA and hyaluronidase-treated HMWHA decreased the number 
of fibrocytes, I investigated the possibility that very small hyaluronic acid 
polymers might inhibit fibrocyte differentiation.  When PBMC were cultured with 
increasing concentrations of 6-mer oligo hyaluronic acid (1,230 Da), there was no 
difference in the number of fibrocytes compared to SFM (Figure 3.3.7).  This 
indicates that although LMWHA inhibits fibrocyte differentiation, the effect 
requires a polymer larger than a 6-mer/1,230 Da hyaluronic acid.  This also 
suggests that hyaluronidase digested HMWHA inhibited fibrocyte differentiation 
(Figure 3.3.3B) due to a size that is similar to LMWHA, and not because of the 
small fragment sizes that are similar to oligo hyaluronic acid.  
 
 
 
 
 
 
 
 
 
 
 
  80 
 
Figure 3.3.7:  Oligo hyaluronic acid does not affect fibrocyte differentiation.  
Human PBMC were cultured in different concentrations of oligo hyaluronic acid 
for 5 days.  After 5 days, the cells were air dried, fixed, stained, and the number 
of fibrocytes was counted.  The results are mean ± SEM of percent control (n = 3 
separate experiments).  The number of fibrocytes 2.5 x 105 PBMC in controls 
from the 3 donors was 4150, 2560, and 575. 
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3.3.6 HMWHA and LMWHA have different effects on the expression of CD44 
Hyaluronic acid binds to the cell-surface molecule CD44, and this 
interaction plays an important role in development, inflammation, tumor growth, 
and the recruitment and activation of many immune cells into injured tissues 
(Lesley et al., 1993).  Therefore I tested the effect of HMWHA and LMWHA on 
the surface levels of CD44 on PBMC.  After culturing PBMC in the presence or 
absence of 300 μg/ml of HMWHA or 300 μg/ml of LMWHA for 5 days, cells were 
stained for CD44.  For PBMC cultured in SFM, both fibrocytes and non-fibrocyte 
cells expressed CD44 (Figure 3.3.8).  In cultures containing HMWHA, fibrocytes 
and non-fibrocyte cells showed staining for CD44 similar to the control (Figure 
3.3.8).  In cultures containing LMWHA, both fibrocytes and non-fibrocyte cells 
had less staining for CD44 compared to the control (Figure 3.3.8).  These results 
indicate that not only do HMWHA and LMWHA have opposite effects on fibrocyte 
differentiation, but they also have different effects on the levels of CD44 on 
fibrocytes and non-fibrocyte cells.  
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Figure 3.3.8. HMWHA and LMWHA have different effects on the expression of 
CD44.  PBMC were incubated in SFM, SFM with 300 μg/ml HMWHA, or SFM 
with 300 μg/ml LMWHA for 5 days.  The PBMC were then fixed and stained for 
CD44.  In all panels, nuclei are stained blue with DAPI and bars are 20 μm. 
Arrows indicate fibrocytes and arrowheads indicate non-fibrocyte cells.  The 
figures represent one of 3 independent experiments.  
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3.3.7 Anti-human CD44 antibodies potentiate fibrocyte differentiation  
 To determine whether the hyaluronic acid binding receptor CD44 could 
directly affect fibrocyte differentiation, I cultured PBMC with two different anti-
human CD44 antibodies, anti-human CD43, or mouse IgG1 isotype control for 5 
days.  I used CD43 as a second hematopoietic marker as it plays an important 
role in adhesion, cell-signaling, and cytoskeleton interactions, but does not bind 
HA (Nong et al., 1989).  One of the anti-human CD44 antibodies (clone 515) is a 
blocking antibody that binds at or near the same site as HA on CD44, preventing 
HA from binding to CD44 (Kansas et al., 1989; Siegelman et al., 1999).  The 
second CD44 mAb (clone G44-26) does not prevent HA binding to CD44.  When 
added to PBMC, both CD44 antibodies significantly increased the number of 
fibrocytes compared to PBMC cultured in either SFM or mouse IgG1 antibodies 
(Figure 3.3.9).  Anti-human CD43 and mouse IgG1 isotype control antibodies had 
no statistically significant effect on fibrocyte differentiation.   
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Figure 3.3.9.  Anti-CD44 antibodies potentiate the differentiation of monocytes to 
fibrocytes.  Human PBMC were cultured in 2 μg/ml anti-human anti-CD44, anti-
CD43, or mouse IgG1 isotype control.  After 5 days, the cells were air dried, 
fixed, stained, and the number of fibrocytes was counted. The results are mean ± 
SEM of percent control (n = 6 separate experiments).  The number of fibrocytes 
per 2.5 x 105 PBMC in controls was 350, 50, 350, 250, 450, and 50.  * indicates p 
< 0.05 compared to control, as determined by ANOVA  with Dunnettʼs post-test). 
Using the Mann Whitney two-tailed t-test, 2 μg/ml anti-human anti-CD44 
antibodies significantly increases the number of fibrocytes when compared to 
control with p < 0.001. 
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 HA can also bind to other surface receptors such as RHAMM (Hardwick et 
al., 1992; Nedvetzki et al., 2004).  I examined if HMWHA or LMWHA affect the 
expression of RHAMM.  After culturing PBMC in the presence or absence of 300 
μg/ml of HMWHA or 300 μg/ml of LMWHA for 5 days, cells were stained for 
RHAMM.  As described previously in activated monocytes (Weiss et al., 1998) or 
CD34+ cells (Greiner et al., 2002), I did not observe any staining for RHAMM in 
fibrocytes or non-fibrocyte cells in the presence or absence of HMWHA or 
LMWHA (data not shown).  
 
3.3.8 Purified monocytes internalize HMWHA and LMWHA  
 As HMWHA and LMWHA directly affect the differentiation of monocytes to 
fibrocytes, I examined if the internalization of HMWHA and LMWHA was different 
in purified monocytes.  Purified monocytes were incubated with or without 300 
μg/ml of HMWHA or 300 μg/ml of LMWHA, and after 30 minutes the cells were 
fixed.  The fixed cells were then stained for hyaluronic acid.  I detected a low 
intensity fluorescence signal on untreated monocytes, which could have been 
due to autofluorescence, non-specific binding of the biotinylated hyaluronic acid 
binding protein (bio-HABP), or the presence of HA bound to the cells ex vivo, as 
these were freshly prepared cells, and HA is present in plasma at 0.01-0.03 
μg/ml (Engstrom-Laurent et al., 1985).  I observed HA staining inside HMWHA 
and LMWHA treated monocytes (Figure 3.3.10).  Monocytes treated with 
HMWHA or LMWHA for 60 minutes also had HA staining inside the cells (data 
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not shown).  This suggests that the opposite effect of HMWHA and LMWHA on 
fibrocyte differentiation is unlikely to be due to differential internalization of high 
and low molecular weight hyaluronic acids by purified monocytes.  Although ten-
day cultured fibrocytes synthesize hyaluronic acid (Bianchetti et al., 2011), our 
inability to detect hyaluronic acid on monocytes cultured for 60 minutes suggest 
that hyaluronic acid production in fibrocytes is developmentally regulated.  
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Figure 3.3.10.  At 30 minutes, both LMWHA and HMWHA are internalized by 
monocytes.  Purified human monocytes were incubated in SFM, SFM with 300 
μg/ml LMWHA, or 300 μg/ml of HMWHA for 30 minutes.  The PBMC were 
stained with biotinylated hyaluronic acid binding protein (HABP) and this was 
detected with streptavidin-FITC.  In all panels, nuclei are stained blue with DAPI 
and bars are 20 μm.  The figures represent one of the 3 independent 
experiments. 
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3.3.9 SAP inhibits HMWHA-induced fibrocyte differentiation and potentiates 
LMWHA-induced fibrocyte inhibition 
A variety of pro-fibrocyte and anti-fibrocyte factors are present during 
tissue injury (Jiang et al., 2007; Niedermeier et al., 2009; Shao et al., 2008; 
Trujillo et al., 2010; Wang et al., 2007a).  I investigated the effect of HMWHA and 
LMWHA on fibrocyte differentiation in the presence of SAP, a potent inhibitor of 
fibrocyte differentiation (Murray et al., 2011; Murray et al., 2010; Naik-Mathuria et 
al., 2008; Pilling et al., 2003; Pilling et al., 2009 ; Pilling et al., 2007; Pilling et al., 
2009; Shao et al., 2008).  PBMC were cultured in different concentrations of 
HMWHA or LMWHA along with different concentrations of SAP. SAP 
counteracted HMWHA-induced fibrocyte differentiation, and potentiated LMWHA-
induced fibrocyte inhibition (Figure 4.3.11).  This suggests that the fibrocyte-
inhibiting activity of SAP has a dominant effect over the fibrocyte-promoting 
activity of HMWHA, and that LMWHA potentiates the ability of SAP to inhibit 
fibrocyte differentiation.   
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Figure 3.3.11.  SAP inhibits HMWHA-induced fibrocyte differentiation and 
potentiates LMWHA-induced fibrocyte inhibition.  (A) Human PBMC were 
cultured in different concentrations of HMWHA with 0, 0.1, 0.3, 1, and 3 μg/ml of 
SAP.  After 5 days, the cells were air dried, fixed, stained, and the number of 
fibrocytes was counted.  The results are mean ± SEM of fibrocytes per 2.5 x 105 
PBMC (n = 5 separate experiments, except n = 11 separate experiments for 
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HMWHA with no SAP).  With no SAP, the difference between no treatment and 
300 μg/ml HMWHA is significant with p < 0.01 (t-test).  With 300 μg/ml HMWHA, 
adding 1 or 3 μg/ml SAP significantly decreases the number of fibrocytes with p < 
0.05 (ANOVA).  Using the non-parametric Mann Whitney two-tailed t-test, with no 
SAP, the difference between no treatment and 300 μg/ml HMWHA is significant 
with p < 0.05.  With 300 μg/ml HMWHA, adding 1 or 3 μg/ml SAP significantly 
decreases the number of fibrocytes with p < 0.05.  (B) Human PBMC were 
cultured in different concentrations of LMWHA with 0, 0.1, 0.3, 1, and 3 μg/ml of 
SAP for 5 days.  After 5 days, the cells were air dried, fixed, stained, and the 
number of fibrocytes was counted.  The results are mean ± SEM of fibrocytes per 
2.5 x 105 PBMC (n = 5 separate experiments, except n = 11 separate 
experiments for LMWHA with no SAP).  With no added SAP, the difference 
between no treatment and 100 μg/ml or 300 μg/ml LMWHA is significant with p < 
0.001 (t-test).  Using the non-parametric Mann Whitney two-tailed t-test, with no 
added SAP, the difference between no treatment and 100 μg/ml or 300 μg/ml 
LMWHA is significant with p < 0.05. 
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3.3.10 LMWHA inhibits IL-4 or IL-13-induced fibrocyte differentiation 
 IL-4 and IL-13 are cytokines that potentiate fibrocyte differentiation (Pilling 
et al., 2003; Pilling et al., 2009 ; Shao et al., 2008).  To determine if there is a 
regulatory hierarchy, I examined the effect of LMWHA on fibrocyte differentiation 
in the presence of IL-4 or IL-13. IL-4 and IL-13 promoted fibrocyte differentiation, 
and LMWHA inhibited IL-4- and IL-13-induced fibrocyte differentiation (Figure 
3.3.12).  This suggests that the fibrocyte inhibiting activity of LMWHA has a 
dominant effect over the fibrocyte promoting activities of IL-4 and IL-13.   
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Figure 3.3.12.  LMWHA inhibits IL-4 or IL-13-induced fibrocyte differentiation.  
Human PBMC were cultured in (A) SFM, SFM with 1 ng/ml IL-4, SFM with 300 
μg/ml LMWHA, or SFM with 1 ng/ml IL-4 and 300 μg/ml LMWHA, or (B) SFM, 
SFM with 1 ng/ml IL-13, or SFM with 1 ng/ml IL-13 and 300 μg/ml LMWHA.  After 
5 days, the cells were air dried, fixed, stained, and the number of fibrocytes was 
counted.  The results are mean ± SEM of percent control (n = 3 separate 
experiments).  The number of fibrocytes per 2.5 x 105 PBMC in controls from the 
3 donors was 900, 1520, and 431.  * indicates p < 0.05, ** p < 0.01, and *** p < 
0.001 compared to control as determined by t-test.  Using the non-parametric 
Mann Whitney two-tailed t-test, there is no significant difference among control, 
300 μg/ml LMWHA, 1 ng/ml IL-4, 1 ng/ml IL-13, the combination of 300 μg/ml 
LMWHA and 1 ng/ml IL-4, or the combination of 300 μg/ml LMWHA and 1 ng/ml 
IL-13.  Using the non-parametric Mann Whitney one-tailed t-test, 300 μg/ml 
LMWHA significantly decreases the number of fibrocytes when compared to 
control with p < 0.05.  Also, the combination of 300 μg/ml LMWHA and 1 ng/ml 
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IL-4 significantly decreases the number of fibrocytes when compared to 1 ng/ml 
IL-4 with p < 0.05.  The combination of 300 μg/ml LMWHA and 1 ng/ml IL-13 also 
significantly decreases the number of fibrocytes when compared to 1 ng/ml IL-13 
with p < 0.05. 
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3.4 Discussion 
I found that 300 μg/ml HMWHA potentiates fibrocyte differentiation and 
300 μg/ml LMWHA inhibits fibrocyte differentiation.  These HA concentrations are 
similar to what has been observed in tissues (Kuo, 2005), and the HA 
concentrations used in other studies (Forrester and Balazs, 1980; Grishko et al., 
2009; McKee et al., 1996; Scheibner et al., 2006; Teder et al., 2002).  The effect 
of these two different sizes of hyaluronic acid on fibrocyte differentiation is a 
direct effect on monocytes.  HMWHA and LMWHA also have different effects on 
the levels of the adhesion receptor CD44.  The opposite effect of HMWHA and 
LMWHA on fibrocyte differentiation does not appear to be due to the difference in 
the internalization of HMWHA and LMWHA by monocytes.  Anti-human CD44 
antibodies potentiate fibrocyte differentiation, suggesting that CD44 may at least 
in part mediate the effect of hyaluronic acid on fibrocyte differentiation.  SAP 
inhibits HMWHA-induced fibrocyte differentiation and potentiates LMWHA-
induced fibrocyte differentiation, while LMWHA inhibits IL-4- or IL-13-potentiated 
fibrocyte differentiation.  These results suggest a dominance hierarchy of SAP > 
LMWHA ≥ HMWHA > IL-4 or IL-13. 
 
HMWHA and LMHWA bind to CD44, TLR2, TLR4, LYVE, and RHAMM 
(CD168) receptors to accomplish their biological effects (Powell and Horton, 
2005).  I have previously shown in chapter 2 that TLR2 and TLR4 agonists do not 
have a direct effect on monocyte to fibrocyte differentiation (Maharjan et al., 
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2010).  Therefore, it is unlikely that HMWHA and LMWHA regulate fibrocyte 
differentiation via TLR2 or TLR4.  We and others have also failed to detect 
RHAMM expression on fibrocytes or human monocytes cultured ex vivo, 
although macrophage cell lines express RHAMM (Greiner et al., 2002; Weiss et 
al., 1998).  Finally LYVE is a HA receptor expressed predominately by lymphatic 
endothelium (Johnson et al., 2007), and we have not detected LYVE on 
monocytes, macrophages, or fibrocytes (data not shown) (Pilling et al., 2009 ).  
As antibodies against CD44 potentiated fibrocyte differentiation, CD44 appears to 
be the dominant receptor for HA induced regulation of fibrocyte differentiation. 
 
Several studies have described differential effects of HMWHA and 
LMWHA on different types of cells such as macrophages, dendritic cells, 
osteoclasts, and T cells (Bollyky et al., 2007; Chang et al., 2007; McKee et al., 
1996; Nakamura et al., 2004; Scheibner et al., 2006; Termeer et al., 2002; 
Termeer et al., 2000).  For example, in murine and human macrophages, 
HMWHA (6 x 106 Da) did not affect the secretion of pro-inflammatory chemokines 
or cytokines (McKee et al., 1996), while LMWHA (< 5 x 105 Da) stimulated these 
cells to produce inflammatory chemokines such as macrophage inflammatory 
protein-1α (MIP-1α), macrophage inflammatory protein-1β (MIP-1β), and 
monocyte chemoattractant protein-1 (MCP-1) (Hodge-Dufour et al., 1997; Kuang 
et al., 2007; McKee et al., 1996; Termeer et al., 2002).  In cultured macrophages, 
HMWHA (4.6 x 105 – 2.8 x 106 Da) inhibited phagocytosis, while LMWHA (9.0 x 
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104 Da) enhanced phagocytosis (Forrester and Balazs, 1980).  The inhibition of 
macrophage phagocytosis was proportional to the molecular weight of the HA.  
These results suggest that LMWHA (< 5 x 105 Da) actively stimulate many types 
of cells at sites of injury to facilitate the clearance of debris and infectious agents, 
while HMWHA (> 106 Da), which is the dominant HA in resolving wounds, acts as 
a signal for repair. 
 
During tissue injury, cirrhosis, and fibrosis, the concentration of HA 
increases in serum and tissue fluids, and this HA appears to be mainly LMWHA 
(Jiang et al., 2007; Scheibner et al., 2006; Stern et al., 2006).  The normal range 
of HA in serum is 0.01-0.1 μg/ml, while in patients with liver injury the serum 
concentration of HA reaches 0.1-0.3 μg/ml (Engstrom-Laurent et al., 1985).  In 
murine models of lung injury, the concentration of HA increased by 50% and the 
size of the accumulated HA was approximately 5.4 x 105 Da (Teder et al., 2002).  
As the injury resolved, the concentration of HA returned to basal levels and the 
size reverted to 1.4 x 106 – 3.1 x 106 Da, (Bai et al., 2005; Teder et al., 2002) 
similar to the size of HA in the lungs of control mice.  These results show that 
following an insult, there is an increase in the concentration of small hyaluronic 
acid fragments.  As the injury resolves, the concentration of HA decreases and 
the size returns back to normal (> 106 Da).  Combined with our results, this 
suggests that the presence of LMWHA at an injured site would inhibit fibrocyte 
differentiation and collagen deposition to allow macrophages to freely move 
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about the injured site to phagocytose debris and clear any infectious agents.  As 
wound healing progresses and the ratio of HMWHA to LMWHA increases 
(Laurent and Fraser, 1992), the HMWHA will promote monocyte to fibrocyte 
differentiation, leading to tissue repair with the fibrocytes secreting ECM and also 
stimulating ECM production by fibroblasts (Hartlapp et al., 2001; Trujillo et al., 
2010; Wang et al., 2007b).  However, there is still no known mechanism to 
explain how a simple repeating disaccharide of varying length has opposing 
effects on a same type of cell. 
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Chapter 4: Serum Amyloid P  (SAP) inhibits neutrophil adhesion and 
diminishes neutrophil accumulation in mice models of acute respiratory 
distress syndrome (ARDS) 
 
4.1 Introduction 
 
Minor infections or injuries to tissues such as the lungs cause the 
damaged cells to recruit immune cells, including neutrophils and monocytes, to 
the injury site.  The neutrophils and monocytes then remove cell debris and 
bacteria from the injured site (Piantadosi and Schwartz, 2004). After the injured 
sites are clear, the neutrophils and monocytes leave and other cells repair the 
wound.   
 
In blood vessels, neutrophils are generally quiescent and circulate in the 
vessel using an adhesion molecule called CD62L to roll along the vessel wall 
(Edwards, 1994; Witko-Sarsat et al., 2000).  When neutrophils get signals from 
injured sites, the neutrophils push through the blood vessel wall and enter the 
injured sites.  Neutrophils are able to push through the blood vessel using an 
adhesion molecule called CD11b (Witko-Sarsat et al., 2000).  Neutrophils can be 
activated by different components of damaged cells or through cytokines such as 
IL-8, TNF-α, or GM-CSF (Cassatella, 1999; Montecucco et al., 2008; Nathan, 
1987; Weisbart et al., 1985; Yong and Linch, 1992).  IL-8 triggers neutrophils to 
migrate into the injured sites (Cassatella, 1999).  TNF-α and GM-CSF increase 
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neutrophil adherence, release of reactive oxygen species, and phagocytosis 
(Montecucco et al., 2008; Nathan, 1987; Weisbart et al., 1985; Yong and Linch, 
1992).  When neutrophils get activated, they increase the number of cell surface 
CD11b molecules and decrease the number of cell surface CD62L molecules 
(Hughes et al., 2006; Strieter and Kunkel, 1994).   Once neutrophils are at injured 
sites, they release reactive oxygen species and proteases, and then engulf 
bacteria and debris by phagocytosis (Hughes et al., 2006; Strieter et al., 1992).    
 
In a normal wound repair resolution, activated neutrophils undergo 
programmed cell death, which prevents the release of reactive oxygen species 
from the neutrophils, thereby preventing any cell damage (Lee and Downey, 
2001). These apoptotic neutrophils are usually cleared by phagocytic cells such 
as macrophages (Rossum et al., 2005).  
 
Since activated neutrophils can cause so much damage to lung cells, we 
need to understand what factors affect neutrophil recruitment and activation.  
Factors such as bacteria and cell debris activate neutrophils and cause the 
release of reactive oxygen species. Neutrophils and monocytes have receptors 
called Fcγ receptors that can recognize bacteria and debris (Tsuboi et al., 2008).  
Fcγ receptors bind to aggregated IgGs, such as IgGs that are attached to 
bacteria. Fcγ receptors can also bind to proteins such as serum amyloid P (SAP), 
a 27 kDa protein that can bind to bacteria and cell debris.  The binding of Fc 
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receptors to aggregated IgG or SAP leads to the engulfment of bacteria and 
debris, but whether this directly activates neutrophil is unknown. 
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4.2 Methods 
4.2.1 Isolating peripheral blood mononuclear cells (PBMC) or neutrophils  
PBMC were isolated and incubated in serum-free media SFM, consisting of 
FibroLife medium as described in chapter 2.2.1 (Shao et al., 2008).  Neutrophils 
were isolated from blood using Lympholyte-poly (Cedarlane Laboratories, 
Hornby, Canada) following the manufacturerʼs directions and re-suspended in 
RPMI-1640 (Sigma) or 2%BSA (Sigma) in RPMI-1640. 
 
4.2.2 Production of human SAP or murine SAP 
Human SAP (hSAP) was from Calbiochem (Calbiochem-EMD Chemicals, 
Darmstadt, Germany).   Commercial human SAP was buffer exchanged with 20 
mM sodium phosphate buffer as described previously (Shao et al., 2008).  
Human SAP (hSAP) or murine SAP (mSAP) were also prepared from 
commercially available human serum (Gemini, West Sacramento, CA) or murine 
serum (Gemini) using calcium-dependent binding to phosphoethanolamine-
conjugated agarose as described previously (Pilling et al., 2007).   Commercial or 
purified SAP was kept at 1 mg/ml concentration in 20 mM sodium phosphate 
buffer, pH 7.4 at -20oC.  
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4.2.3 Neutrophil spreading assay with cell debris 
PBMC at 1 x 106 cells/ml in SFM were dounced with a drill and a Teflon douncing 
bit for 60 strokes to make cell debris. 100 μl of PBMC at 0.5 x 106 cells/ml were 
incubated in flat bottom 96-well tissue culture plates (BD, Franklin Lakes, NJ) in 
the presence or absence of 100 μl of undiluted debris for 7 days at 37oC.  On day 
7, the supernatants were pipetted into eppendorf tubes and centrifuged at 10,000 
x g for 10 minutes.  Supernatants were again carefully pipetted out of the 
centrifuged eppendorf tubes and aliquoted into new eppendorf tubes.  These 
eppendorf tubes containing PBMC supernatants were then flash frozen with 
liquid nitrogen, and stored at -80oC until further use.  100 μl of 0.5 x 106 cells/ml 
neutrophils in RPMI were incubated with 50 μl of 40 μg/ml SAP in RPMI (from a 1 
mg/ml stock of SAP in 20 mM sodium phosphate buffer, pH 7.4), and 50 μl RPMI, 
50 μl of PBMC supernatant and 50 μl RPMI, 100 μl RPMI, or 50 μl of PBMC 
supernatant and 50 μl of 40 μg/ml SAP.  After 1 hour, fields of neutrophils were 
photographed using a phase-contrast microscope with a 20 x objective. 
 
4.2.4 Neutrophil adhesion assay on wet plasma fibronectin or cellular fibronectin 
Wells of flat bottom 96-well tissue culture plates (BD) were pre-coated with 50 μl 
of 20 μg/ml bovine plasma fibronectin (Sigma) in PBS or 20 μg/ml cellular human 
foreskin fibroblast fibronectin (Sigma) in PBS for 1 hour at 37oC.  After removing 
the fibronectin, the wells were washed three times with 200 μl of PBS and then 
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blocked with 200 μl of 2% BSA-PBS for 2 hours at room temperature.  The wells 
were then washed three times with 200 μl of PBS and once with 200 μl of 2% 
BSA-RPMI before adding neutrophils.  500 μl of neutrophils at 1 x 106 cells/ml in 
2% BSA-RPMI were incubated in an eppendorf tube (pre-incubated with 2% 
BSA-RPMI for 2 hours at 37oC) with 30 μg/ml SAP (from a 1 mg/ml stock made in 
20 mM sodium phosphate buffer pH 7.4 of Calbiochem SAP or SAP purified from 
human serum) or an equal volume of buffer for 30 minutes at 37oC immediately 
after isolating neutrophils. 100 μl of the neutrophils incubated with or without 30 
μg/ml SAP was then incubated in the presence or absence of 1 μl of 10 µg/ml 
recombinant human-TNF-α (stock recombinant human-TNF-α was reconstituted 
to 100 μg/ml in water, 300-01, Peprotech, NJ) in 2% BSA-RPMI for 30 minutes at 
37oC in the well of a 96-well tissue culture plate. After a 30-minutes incubation 
with TNF-α, non-adherent neutrophils were removed and the wells were washed 
three times by pipetting in and then removing 100 μl of PBS.  The plate was then 
air-dried, stained with methylene blue and eosin (Richard-Allan Scientific, 
Kalamazoo, MI) (Fischer et al., 2008), and the number of adherent neutrophils 
was counted in five different 900 μm diameter fields of view.  
 
4.2.5 Neutrophil adhesion assay on dry cellular fibronectin  
Wells of 96-well tissue culture plates were pre-coated with 60 μl of 20 μg/ml 
cellular fibronectin for 2 hours at room temperature. The fibronectin was then 
removed, and the wells were washed three times with 200 μl of PBS, and then 
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blocked with 1% BSA-PBS for 1 hour at room temperature.  After blocking, BSA 
was removed, the wells were air-dried, and then washed three times with 100 μl 
of PBS per well.  The wells were washed in 1% BSA-RPMI before adding 
neutrophils.  Neutrophils at a concentration of 2 x 106 cells/ml in 1% BSA-RPMI 
were incubated in an eppendorf tube (pre-incubated with 1% BSA-RPMI for 2 
hours at 37oC) with 30 μg/ml SAP (from a 1 mg/ml stock made in 20 mM sodium 
phosphate buffer) or an equal volume buffer for 30 minutes at 37oC. 50 μl of 
neutrophils incubated with or without 30 μg/ml SAP was then incubated in the 
presence or absence of 0.5 μl of 10 μg/ml TNF-α in 1% BSA-RPMI for 30 
minutes at 37oC in a 96-well tissue culture plate. After 30 minutes, non-adherent 
neutrophils were removed and the plates were washed three times by pipetting in 
and then removing 100 μl PBS, air-dried, stained, and the number of adherent 
neutrophils was counted.  
 
4.2.6 Staining for neutrophil adhesion molecules 
500 μl of neutrophils at 2.0 x 106 cells/ml were aliquoted into eppendorf tubes 
(pre-coated with 2% BSA-RPMI for 1 hour at 37oC) and incubated in  10 ng/ml or 
1 ng/ml TNF-α, 100 ng/ml IL-8, or 10 ng/ml or 1 ng/ml GM-CSF in the presence 
or absence of 10 μg/ml or 60 μg/ml SAP for one hour at 37oC.  For the 
neutrophils that were stained with (anti-human) anti-CD18, anti-CD61, or anti-
CD44, 500 μl of neutrophils at 2.0 x 106 cells/ml were aliquoted into the 
eppendorf tubes (pre-coated with 2% BSA-RPMI for 1 hour at 37oC) and treated 
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with 30 μg/ml SAP or equal volume buffer for 30 minutes at 37oC.  Neutrophils 
were then divided into 3 eppendorf tubes (pre-coated with 2% BSA-RPMI for 1 
hour at 37oC) and incubated for 30 minutes with 10 ng/ml TNF-α, 10 nM fMLP, or 
an equal volume buffer at 37oC. These neutrophils were then washed with ice-
cold 1 x PBS and collected by centrifugation at 500 x g for 5 minutes.  The 
supernatant was carefully removed, and the neutrophils were re-suspended in 1 
ml of 4% BSA-PBS.  Neutrophils from each condition were equally divided into 
new eppendorf tubes (pre-coated with 4% BSA-PBS for 1 hour at 4oC) and 
stained with 5 μg/ml primary antibodies against CD11b (Biolegend), CD62L (BD 
Biosciences), CD32 (BD Biosciences), CD18 (Biolegend), CD61 (BD 
Biosciences), CD44 (BD Biosciences), or mouse IgG1 isotype control 
(Biolegend), and then incubated with 2.5 μg/ml FITC-conjugated F(ab′)2 goat 
anti-mouse IgG antibodies (cross-adsorbed against human Ig, Southern 
Biotechnology, Birmingham, AL, USA) as described previously (Maharjan et al., 
2010; Shao et al., 2008) and analyzed with a flow cytometer (Accuri Cytometers).    
 
4.2.7 Quantifying the production of hydrogen peroxide 
Wells of black 96-well cell culture plates (Nalge Nunc, Rochester, NY) were pre-
coated with 50 μl of 20 μg/ml plasma fibronectin for 1 hour at 37oC. The 
fibronectin was then removed, and the wells were washed three times with 200 μl 
of PBS, and then washed once with Krebs-Ringer phosphate glucose (KRPG) 
buffer (145 mM NaCl, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM MgSO4, 5.77 mM 
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sodium phosphate buffer, and 5.5 mM glucose, pH 7.35 (Nathan, 1987), before 
adding the neutrophils.  500 μl of neutrophils at a concentration of 15 x 105 
cells/ml in KRPG buffer were incubated in an eppendorf tube (pre-incubated with 
2% BSA-KRPG buffer for 2 hours at 37oC) with 30 μg/ml SAP (from a 1 mg/ml 
stock made in 20 mM sodium phosphate buffer) or an equal volume of buffer for 
30 minutes at 37oC. An assay mixture of 100 μl of KRPG buffer, 20 μl of 300 μM 
scopoletin (Sigma), 20 μl of 10 mM NaN3, and 20 μl of 10 U/ml horse radish 
peroxidase (Sigma) were aliquoted into a well and the plate was equilibrated to 
37oC for 5 minutes as described previously (Delaharpe and Nathan, 1985; 
Nathan, 1987). 20 μl of neutrophils incubated with or without 30 μg/ml SAP was 
then added to the assay mixture in the presence or absence of 20 μl of 1 μg/ml 
TNF-α in KRPG buffer, 20 μl of 1 μM formyl-Met-Leu-Phe (fMLP) (Sigma) in 
KRPG buffer, 20 μl of 1 µM phorbol 12-myristate 13-acetate (PMA) (Sigma), 20 
μl of 1 μM phorbol 12,13-dibutyrate (PDBu) (Sigma), or 20 μl of KRPG buffer.  
The 96-well plate was incubated at 37oC and the fluorescence (excitation: 360 
nm emission: 460 nm) was monitored every 10 minutes for 3 hours using a 
Synergy MX plate reader (BioTek, Winooski, VT). 
 
4.2.8 Transmigration assay of neutrophils 
 
50 μl of neutrophils at 1 x 106 cells/ml in 2%BSA-RPMI was added on the top 
chamber of the 3 μm nylon membrane (BD) in the presence or absence of 10 nM 
fMLP, 30 μg/ml SAP, 10 nM fMLP and 30 μg/ml SAP, or an equal volume buffer 
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in 2% BSA-RPMI.   The bottom chamber contained 600 μl of 10 nM fMLP, 30 
μg/ml SAP, or 10 nM fMLP and 30 μg/ml SAP, or an equal volume buffer in 2% 
BSA-RPMI.  The transmigration was carried out for 2 hours at 37oC.  The top 
chamber was removed and 25 μl of the neutrophils that had migrated into the 
bottom chamber was then counted with a flow cytometer (Accuri Cytometers).   
 
4.2.9 Murine neutrophil adhesion assay 
Mice were euthanized and blood was obtained via cardiac puncture.  2-4 ml of 
blood was collected in an EDTA-containing vacutainer tube (BD) and the red 
blood cells (RBC) in 2 ml of blood were lysed by adding 1 ml of ammonium 
chloride, potassium bicarbonate (ACK) lysis buffer (15 mM NH4Cl, 1 mM KHCO3, 
0.01 mM Na2EDTA) and incubating for 3 minutes at room temperature.  
Eppendorf tubes containing blood and ACK lysis buffer were centrifuged at 500 x 
g for 5 minutes at room temperature, and the supernatant containing lysed RBC 
was removed.   The pellets were re-suspended in 200 μl PBS, and 1 ml ACK 
lysis buffer was added.  After three minutes, cells were collected by 
centrifugation.  This was then repeated two additional times.  Cells were re-
suspended in 1 ml PBS and then collected by centrifugation.  The cells were then 
re-suspended in 1 ml of 2% BSA-RPMI.  A neutrophil adhesion assay was 
carried out in 2% BSA-RPMI similar to the human neutrophil adhesion assay 
using 60 μg/ml human SAP instead of 30 μg/ml.   The adhered cells were stained 
for Ly6G to distinguish neutrophils from other cell types as described previously 
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(Pilling et al., 2009 ).  The number of adhered Ly6G-positive neutrophils was then 
counted as described above.  
 
4.2.10 Animal model of acute respiratory distress syndrome (ARDS) 
ARDS-like pathology was induced in 4 weeks old C57/BL6 mice (The Jackson 
Laboratory, Bar Harbor, ME) with an oropharyngeal aspiration of 50 µl of 0.2 
U/kg or 3 U/kg bleomycin (Calbiochem) (Pilling et al., 2009 ).  Mice were 
anesthetized and laid on a 60o inclined board.  The mouth of the mouse was 
opened using a thin rubber band that held the upper front teeth of the mouse.  
During oropharyngeal aspiration, the nares of the mouse were pinched shut with 
a pair of forceps and the tongue was gently extracted out with another pair of 
forceps as described previously (Lakatos et al., 2006).  With a pipettor, bleomycin 
was quickly aspirated through the mouth of the mouse.  The successful 
aspiration of bleomycin into the lungs was confirmed by listening to the crackling 
noise heard after the aspiration.  The mice were used in accordance with 
guidelines published by the National Institutes of Health, and the protocol was 
approved by the Texas A&M University Animal Use and Care Committee.  
4.2.11 Injections of SAP  
At 24 and 48 hours following bleomycin aspiration (days 1 and 2), C57/BL6 or 
sap-/- mice were treated with an intraperitoneal injection of 50 μl of 1 mg/ml hSAP 
or mSAP in 20 mM sodium phosphate buffer or an equal volume of 20 mM 
sodium phosphate buffer. 
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4.2.12 Quantification of different types of cells  
Mice were euthanized at day 3 after bleomycin aspiration, and the lungs were 
perfused with 400 μl of PBS for three times to collect cells by bronchoalveolar 
lavage (BAL) as described previously (Corteling et al., 2002).  The cells were 
collected by centrifugation at 500 x g for 5 minutes, and the supernatants were 
transferred to eppendorf tubes.  The pooled supernatants were flash frozen with 
liquid nitrogen, and stored at -80oC until further use.  The cells collected from 
BAL were re-suspended in 100 μl of 4%BSA-PBS and counted with a 
hemacytometer.  The cells were then diluted in a total volume of 600 μl of 4% 
BSA-PBS.  100 μl of diluted cells were then aliquoted into cytospin funnels and 
were then spun onto glass slides (Superfrost plus white slides, VWR, West 
Chester, PA) at 400 x g for 5 minutes using a cytospin centrifuge (Shandon 
Southern Products Ltd, Cheshire, England).  These cells were then air-dried, and 
stained with 5 μg/ml anti-mouse Ly6G (Biolegend, San Diego, CA) as previously 
described (Pilling et al., 2009 ).  After staining the cells, the number of cells 
positive for Ly6G per 200 cells was counted.   The percent of positive cells was 
then multiplied by the total number of cells recovered from the BAL to obtain the 
number of neutrophils in the BAL.  
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4.2.13 Immunohistochemistry 
After BAL, lungs were inflated with pre-warmed OCT (VWR) and then embedded 
in OCT, frozen on dry ice, and stored at -80oC as described previously (Pilling et 
al., 2007).  Lung tissue sections (6 μm) were prepared and 
immunohistochemistry was done as described previously (Pilling et al., 2007) 
except slides were incubated with 2.5 μg/ml primary antibodies in 4% BSA-PBS 
for 60 minutes.  The lung sections were stained for Ly6G (BioLegend) to detect 
neutrophils, CD11b (BioLegend) to detect macrophages, and CD45 (BioLegend) 
to detect all leukocytes.  Isotype-matched mouse irrelevant antibodies were used 
as controls.  Slides were then washed three times with PBS over 30 minutes and 
incubated with 1.25 μg/ml biotinylated mouse F(abʼ)2 anti-rat IgG in 4% BSA-
PBS for 30 minutes.   Slides were then washed three times in PBS over 30 
minutes and incubated with a 1:500 dilution of streptavidin alkaline phosphatase 
(Vector Laboratories) in 4% BSA-PBS for 30 minutes.  Staining was developed 
with a VectorRed Alkaline Phosphatase Kit (Vector Laboratories) for 10 minutes.  
Slides were then mounted on permount as described previously. 
 
4.2.14 Statistics 
Statistical analysis was performed using Prism (GraphPad Software, San Diego, 
CA, USA).  Statistical significance was determined using either analysis of 
variance (ANOVA) or t-test, and significance was defined as p < 0.05.  
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4.3 Results 
4.3.1 SAP inhibits neutrophil spreading induced by PBMC conditioned media  
Factors such as bacteria and cell debris elicit the release of different 
factors that signal neutrophil to spread, adhere, and migrate to the sites of 
infection or injury (Perl et al., 2008).  We previously found that a protein in 
plasma called serum amyloid P (SAP) inhibits the differentiation of monocytes to 
fibrocytes (Pilling et al., 2003).  Since neutrophils have Fcγ receptors that can 
bind to proteins such as serum amyloid P (SAP), we examined the effect of SAP 
on neutrophil spreading.  To determine the role of SAP on neutrophil spreading, 
David Roife and Dr. Gomer incubated human PBMC with cell debris for 7 days at 
37oC.  On the 7th day, they removed the conditioned media (which should contain 
cell debris as well as PBMC-derived signals elicited in response to debris) and 
incubated freshly isolated human neutrophils in the presence or absence of 10 
μg/ml SAP, PBMC conditioned media, or the combination of PBMC conditioned 
media and 10 μg/ml SAP.  They observed that there were neutrophils that were 
spreading in the control experiment, which could have been an effect of laying 
neutrophils directly on a plastic tissue culture plate (Figure 4.3.1). When 
neutrophils were incubated with 10 μg/ml SAP, the neutrophils had a rounded 
morphology and decreased neutrophil spreading (Figure 4.3.1). This suggests 
SAP is directly acting on the neutrophils to inhibit the spreading.  When 
neutrophils were incubated with PBMC conditioned media, there were increased 
numbers of neutrophils that were spreading (Figure 4.3.1).  However, when 
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neutrophils were incubated with the combination of PBMC conditioned media and 
10 μg/ml SAP, SAP significantly inhibited the spreading of neutrophils induced by 
the PBMC conditioned media (Figure 4.3.1). Overall, these results suggest that 
SAP inhibits neutrophil spreading.   
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Figure 4.3.1: SAP inhibits neutrophil spreading.  Human PBMC were isolated and 
incubated in the presence of cell debris for 7 days at 37oC.  On the 7th day, the 
conditioned media was removed.  Human neutrophils were incubated in the 
presence or absence of 10 μg/ml human SAP (hSAP), PBMC conditioned media, 
or the combination of PBMC conditioned media for 1 hour at 37oC.  Fields of 
neutrophils were photographed using a phase-contrast microscope with a 20 x 
objective at 1 hour.  Arrows indicate spread neutrophils.  All of the figures 
represent one of 3 separate experiments.  Bar is 20 µm.  Figure is from Dr. 
Richard H. Gomer and David Roife.  
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4.3.2 SAP inhibits neutrophil adhesion induced by TNF-α 
TNF-α increases the adherence of neutrophils on a variety of extracellular 
matrices (Kettritz et al., 2004; Nathan, 1987). Since we observed that SAP 
inhibits neutrophil spreading, we wanted to determine the role of SAP in 
neutrophil adhesion.  Freshly isolated neutrophils were incubated with or without 
30 μg/ml of SAP for 30 minutes at 37oC.  These neutrophils were then incubated 
with 100 ng/ml TNF-α for 30 minutes at 37oC in plates pre-coated with BSA, 
plasma fibronectin, or cellular fibronectin.  Neutrophils incubated with TNF-α had 
increased number of neutrophils that adhered to the wells (Figure 4.3.2A-C).  
When the 96 well plates were coated with BSA or cellular fibronectin, neutrophils 
treated with 30 μg/ml SAP had no significant change in neutrophil adherence 
when compared to the control (Figure 4.3.2A and 4.3.2C).  However, when the 
96 well plates were coated with plasma fibronectin, treatment of neutrophils with 
30 μg/ml SAP decreased the number of adhered neutrophils compared to the 
control (Figure 4.3.2B).  When neutrophils pre-treated with SAP were incubated 
with 100 ng/ml TNF-α, SAP significantly inhibited the TNF-α-induced adhesion of 
neutrophils to BSA, plasma fibronectin, and cellular fibronectin (Figure 4.3.2A-C).  
Similarly, Dr. Derrick Brazilis also found that SAP pre-treatment inhibited 
neutrophil adhesion induced by TNF-α in 96 well culture plates that had been 
pre-coated with cellular fibronectin and had been air-dried before adding 
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neutrophils (Figure 4.3.3).  These results suggest SAP inhibits neutrophil 
adhesion induced by TNF-α.   
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Figure 4.3.2. SAP inhibits neutrophil adhesion induced by TNF-α. (A) 96-well 
tissue culture plates were blocked with 2% BSA-PBS for 2 hours at room 
temperature.  The plates were washed in PBS, and once with 2% BSA-RPMI.  
Human neutrophils were pre-treated with or without 30 μg/ml hSAP for 30 
minutes at 37oC.  100 μl of 1 x 106 cell/ml neutrophils were seeded on the plate, 
and 1 μl of 10 μg/ml recombinant human-TNF-α was added to the neutrophils for 
another 30 minutes at 37oC. After removing the media and washing the plates, 
the plates were air-dried, fixed, stained, and the number of neutrophils that 
remained in the wells was counted (n = 4). (B)  96-well tissue culture plates were 
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pre-coated with 20 μg/ml plasma fibronectin and then blocked with 2% BSA-PBS 
for 2 hours at room temperature.  Neutrophils were incubated in the presence or 
absence of 30 μg/ml SAP or 100 ng/ml TNF-α and counted as described above 
(n = 23).  Using two-tailed t-test, SAP significantly inhibited neutrophil adhesion 
when compared to the control with p < 0.05.  (C) 96-well tissue culture plates 
were pre-coated with 20 μg/ml cellular fibronectin and then blocked with 2% 
BSA-PBS for 2 hours at room temperature.  Neutrophils were incubated in the 
presence or absence of 30 μg/ml SAP or 100 ng/ml TNF-α and counted as 
described above (n = 5).  When the number of neutrophils treated with TNF-α, 
SAP, SAP and TNF-α, or control was normalized to the number of neutrophils 
treated with TNF-α, there was a significant difference in the number of adhered 
neutrophils (1-way ANOVA, Tukeyʼs test). ** indicates p < 0.01, and *** indicates 
p < 0.001.  
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Figure 4.3.3: SAP inhibits neutrophil adhesion induced by TNF-α on dry 
fibronectin. 96-well tissue culture plates were pre-coated with 20 μg/ml cellular 
fibronectin and then blocked with 2% BSA-PBS for 2 hours at room temperature.  
The plate was then air-dried.  Human neutrophils were pre-incubated in the 
presence or absence of 30 μg/ml SAP, plated on the 96-well tissue culture plate, 
and stimulated with 100 ng/ml TNF-α for 30 minutes at 37oC.  Non-adhered 
neutrophils were removed and adhered neutrophils were counted as described in 
Figure 4.3.2 (n = 3). When the number of neutrophils treated with TNF-α, SAP, 
SAP and TNF-α, or control was normalized to the number of neutrophils treated 
with TNF-α, there was a significant difference in the number of adhered 
neutrophils (1-way ANOVA, Tukeyʼs test). *** indicates p < 0.001.  Figure is from 
Dr. Derrick Brazilis. 
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4.3.3 SAP inhibits murine neutrophil adhesion induced by TNF-α 
Since we found that human SAP can inhibit human neutrophil adhesion 
induced by TNF-α, we wanted to determine if human SAP could also inhibit 
murine neutrophil adhesion induced by TNF-α.  Freshly isolated murine 
neutrophils were incubated with or without 60 μg/ml of human SAP for 30 
minutes at 37oC.  These neutrophils were then incubated with 100 ng/ml TNF-
α for 30 minutes at 37oC in plates pre-coated with plasma fibronectin. There was 
an increased number of neutrophils that adhered to the wells when neutrophils 
were treated with TNF-α (Figure 4.3.4).  Neutrophils treated with 60 μg/ml SAP 
had no significant change in neutrophil adherence when compared to the control 
(Figure 4.3.4). However, when neutrophils pre-treated with SAP were incubated 
with 100 ng/ml TNF-α, SAP significantly inhibited the TNF-α-induced adhesion of 
neutrophils to plasma fibronectin (Figure 4.3.4).  These results suggest that 
human SAP inhibits murine neutrophil adhesion induced by TNF-α.  
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Figure 4.3.4 Human SAP inhibits murine neutrophil adhesion induced by TNF-α. 
96-well tissue culture plates were pre-coated with 20 μg/ml plasma fibronectin 
and then blocked with 2% BSA-PBS for 2 hours at room temperature.  Murine 
blood was lysed with ACK lysis buffer and isolated cells were incubated in the 
presence or absence of 60 μg/ml SAP for 30 minutes at 37oC.  Cells were then 
plated on a 96-well tissue culture plate in the presence or absence of 100 ng/ml 
TNF-α for 30 minutes at 37oC.  Non-adhered cells were removed, and adhered 
cells were stained for Ly6G (a marker for murine neutrophils).  The number of 
adhered neutrophils was counted as described in Figure 4.3.2 (n = 8). There was 
a significant difference in the number of adhered neutrophils (1-way ANOVA, 
Tukeyʼs test).  * indicates p < 0.05 and ** indicates p < 0.01. 
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4.3.4 SAP has no effect on adhesion molecules induced by TNF-α or GM-CSF 
To determine how SAP decreases the number of adherent neutrophils in 
the neutrophil plate adhesion assay, I analyzed receptors whose levels change in 
activated neutrophils. CD11b are adhesion molecules that help neutrophils to 
extravagate into injured sites, while CD62L help neutrophils to roll inside blood 
vessels when the cells are in a quiescent phase (Hughes et al., 2007; Taylor et 
al., 2007a). CD32 are the major Fc receptors of neutrophils (Tsuboi et al., 2008).  
Neutrophils were treated with 10 ng/ml or 1 ng/ml TNF-α, 100 ng/ml IL-8, or 10 
ng/ml or 1 ng/ml GM-CSF in the presence or absence of 10 μg/ml or 60 μg/ml 
SAP for one hour at 37oC.  After the reaction was stopped, the cells were stained 
for CD11b, CD32, and CD62L.  When neutrophils were treated with  10 ng/ml or 
1 ng/ml TNF-α , 100 ng/ml IL-8, or 10 ng/ml or 1 ng/ml GM-CSF in the presence 
or absence of 10 μg/ml or 60 μg/ml SAP, there was no significant effect on the 
number of CD11b-positive cells (Figure 4.3.5A).  However, the staining intensity 
of CD11b was different in various conditions (Figure 4.3.6A). IL8 in the presence 
or absence of SAP had no effect on the levels of CD11b or CD62L compared to 
untreated neutrophils (Figure 4.3.6A).  TNF-α or GM-CSF treated neutrophils 
with or without SAP had increased levels of CD11b compared to other conditions 
(Figure 4.3.6A).  This suggests that TNF-α and GM-CSF activate neutrophils, 
and that the addition of SAP has no effect on the activation.  When neutrophils 
were treated with 10 ng/ml or 1 ng/ml TNF-α or 10 ng/ml or 1 ng/ml GM-CSF in 
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the presence or absence of 60 μg/ml SAP, there was a decrease in the number 
of CD62L-positive cells in these conditions (Figure 4.3.5B).  Cells treated with 
TNF-α or GM-CSF in the presence or absence of SAP had decreased levels of 
CD62L compared to other conditions (Figure 4.3.6A).  This again suggests that 
TNF-α and GM-CSF activate neutrophils, and that the addition of SAP has no 
effect on the activation.   There was no significant effect on the levels of CD32 or 
mouse IgG1 (control) staining when neutrophils were treated with 10 ng/ml TNF-
α or 10 ng/ml IL-8 in the presence or absence of 60 μg/ml SAP (Figure 4.3.5C, 
4.3.5D, and 4.3.6B). TNF-α and GM-CSF increased the levels of CD11b and 
decreased the levels of CD62L-positive cells.  This suggests that TNF-α and GM-
CSF activate neutrophils (Cassatella, 1999; Montecucco et al., 2008; Yong and 
Linch, 1992), and that the addition of SAP has no effect on the activation.  
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Figure 4.3.5:  SAP has no effect on the number of surface receptors associated 
with neutrophil activation.  (A) Human neutrophils were treated with 100 ng/ml IL-
8, 10 ng/ml or 1 ng/ml GM-CSF, or 10 ng/ml or 1 ng/ml TNF-α in the presence or 
absence of SAP (10 μg/ml for IL-8 and 60 μg/ml for GM-CSF and TNF-α) for 1 
hour at 37oC.  The cells were then stained for CD11b.  The results are mean ± 
SEM of percent control of CD11b-positive cells (n = 3 separate experiments). (B) 
Neutrophils were treated with GM-CSF (10 ng/ml or 1 ng/ml) or TNF-α (10 ng/ml 
or 1 ng/ml) in the presence or absence of SAP (60 μg/ml) for 1 hour at 37oC.  The 
cells were then stained for CD62L. The results are mean ± SEM of percent 
control of CD62L-positive cells (n = 3 separate experiments). (C) Neutrophils 
B.  
C.   D. 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were treated with IL-8 (100 ng/ml) or TNF-α (10 ng/ml) in the presence or 
absence of SAP (10 μg/ml) for 1 hour at 37oC.  The cells were then stained for 
CD32.  The results are mean ± SEM of percent control of CD32-positive cells (n 
= 2 separate experiments). (D) Neutrophils were treated with the above 
conditions as in Fig. 4.3.5C for 1 hour at 37oC.  The cells were then stained with 
mouse IgG1.  The results are mean ± SEM of percent control of mouse IgG1-
positive cells (n = 2 separate experiments).  
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Figure 4.3.6: SAP has no effect on the levels of CD11b, CD62L, or CD32.  (A) 
Human neutrophils were treated with the above conditions as in Fig. 4.3.5A for 1 
hour at 37oC.  The cells were then stained for CD11b or CD62L.  The results are 
mean ± SEM of percent control of median fluorescence intensity of CD11b- or 
CD62L-positive cells (n = 3 separate experiments except n = 2 for IL-8 and IL-
8+SAP).  (B) Neutrophils were treated with the above conditions as in Fig. 4.3.5C 
for 1 hour at 37oC.  The cells were then stained for CD32 or stained with a control 
mouse IgG1.  The results are mean ± SEM of percent control of median 
fluorescence intensity of CD32- or mouse IgG1-positive cells (n = 2 separate 
experiments).  
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4.3.5 SAP has no effect on the levels of the surface receptors CD18, CD61, or 
CD44. 
  
 Since SAP had no effect on the levels of the surface receptors CD11b or 
CD62L, I examined the levels of other adhesion molecules such as CD18, CD61, 
or CD44.  CD18 is an integrin molecule that binds to CD11b and aids in leukocyte 
migration (Johnson and Ruffell, 2009).  CD61 is also an integrin molecule that 
facilitates leukocyte migration (Johnson and Ruffell, 2009), but little is known 
about its role in neutrophil migration. CD44 is a cell surface adhesion receptor 
that also helps in leukocyte migration (Johnson and Ruffell, 2009), but again little 
is known about its role in neutrophil migration. Freshly isolated human 
neutrophils were treated with or without 30 μg/ml SAP for 30 minutes at 37oC.  
After 30 minutes, 10 ng/ml TNF-α or 10 nM formyl-Met-Leu-Phe (fMLP) was 
added to cells with or without SAP and incubated for another 1 hour at 37oC.  
Neutrophils were removed and stained for CD18, CD61, or CD44.  Neutrophils 
treated with TNF-α showed increased levels of the surface receptor CD18 and 
decreased levels of the surface receptor CD44 (Figure 4.3.7).  The levels of 
CD61 did not change with the addition of TNF-α. SAP had no effect on the levels 
of the surface receptors CD18, CD61, or CD44.  Neutrophils treated with TNF-α 
and SAP showed increased levels of CD18 and decreased levels of CD44.  The 
levels of CD61 did not change with the addition of TNF-α or SAP.  Neutrophils 
treated with fMLP showed a slight increase in the levels of CD18, but there was 
no change with the levels of CD61or CD44.   Neutrophils treated with fMLP and 
SAP also showed a slight increase in the levels of CD18, but there was no 
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change with the levels of CD61, or CD44.  Adding SAP to neutrophils treated with 
TNF-α or fMLP had no effect on the levels of the surface receptors CD18, CD61, 
or CD44.    
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Figure 4.3.7: SAP has no effect on the levels of CD18, CD 61, or CD44.  
Neutrophils pre-treated with or without SAP were incubated in the presence or 
absence of TNF-α (10 ng/ml) or fMLP (10 nM) for 1 hour at 37oC.  The cells were 
then stained for anti-human CD18, anti-human CD61, or anti-human CD44.  The 
results are mean ± SEM of median fluorescence intensity of positively stained 
cells (n = 3 separate experiments for CD18 and CD61 and n = 2 separate 
experiments for CD44).  
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4.3.6 In neutrophils, SAP has no effect on the production of hydrogen peroxide 
induced by TNF-α 
Activated neutrophils release reactive oxygen species such as hydrogen 
peroxide and superoxide anions through NADPH oxidase (Waddell et al., 1994).  
The enzyme produces reactive oxygen species to kill microbes such as bacteria.  
However, excessive release of these cytotoxic products can further damage an 
injured tissue.  To examine whether SAP can inhibit the production of hydrogen 
peroxide induced by TNF-α, fMLP, PDBu, or PMA, we examined the change in 
the fluorescence intensity of scopoletin, a fluorescent molecule that gets modified 
by hydrogen peroxide. I used the fluorescence arbitrary unit to obtain hydrogen 
peroxide produced per 1.5 x 104 cells as previously described (Nathan et al., 
1989; Nathan, 1987). There was an increase in the production of hydrogen 
peroxide when cells were treated with TNF-α, fMLP, PDBu, or PMA (Figure 
4.3.8).  SAP had no effect on the production of hydrogen peroxide induced by 
TNF-α (Figure 4.3.8A), fMLP (Figure 4.3.8B), PDBu (Figure 4.3.8C), or PMA 
(Figure 4.3.8D). 
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Figure 4.3.8: SAP has no effect on the production of hydrogen peroxide induced 
by TNF-α, PMA, PDBu, or FMLP.  (A) Neutrophils pre-treated with 30 μg/ml SAP 
were treated with 10 ng/ml TNF-α for 3 hours at 37oC. Fluorescence intensity 
was measured every 10 minutes. (B) Neutrophils pre-treated with 30 μg/ml SAP 
were treated with 10 nM fMLP for 3 hours at 37oC. The results are hydrogen 
peroxide produced in different condition every 10 minutes for 3 hours. (C) 
Neutrophils pre-treated with 30 μg/ml SAP were treated with 10 nM PDBu for 3 
hours at 37oC. (D) Neutrophils pre-treated with 30 μg/ml SAP were treated with 
10 nM PMA for 3 hours at 37oC. (All of the figures represent one of the 2 
separate experiments). 
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4.3.7 SAP has no effect on the migration of neutrophils.  
 
The formyl peptide fMLP induces the migration of neutrophils (Quinn et al., 
2007). To determine the role of SAP in neutrophil migration, I carried out 
migration assays using a Boyden chamber.  Neutrophils are placed on a porous 
membrane and the bottom of the membrane touches a solution containing buffer 
or fMLP in the presence or absence of SAP.  Migration was carried out for 2 
hours at 37oC and 25 μl of cells from the bottom chamber was counted with a 
flow cytometer.  fMLP significantly increased the number of neutrophils that 
migrated across the porous membrane, while SAP had no effect on the migration 
of neutrophils (Figure 4.3.9).  SAP also had no affect on the migration of 
neutrophils caused by fMLP (Figure 4.3.9).   
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Figure 4.3.9: SAP has no effect on the migration of neutrophils. Neutrophils were 
placed on a porous membrane that touched a chamber containing buffer, 10 nM 
FMLP, 30 μg/ml SAP, or 10 nm fMLP and 30 μg/ml SAP.  Migration was carried 
out for 2 hours at 37oC.  25 μl of neutrophils from the bottom chamber were 
counted with a flow cytometer.  The results are mean ± SEM of migrated 
neutrophils (n = 4 separate experiments).  
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4.3.8 SAP inhibits the accumulation of Ly6G-positive cells in lungs of mice 
treated with bleomycin 
In acute lung injury and acute respiratory distress syndrome (ARDS), there 
is a massive accumulation of neutrophils in the lungs that further worsens the 
condition by producing superoxide anions and hydrogen peroxide (Lee and 
Downey, 2001; Perl et al., 2008).  Since SAP inhibits neutrophil adhesion, we 
examined the effect of SAP on bleomycin-induced neutrophil accumulation in the 
lungs of mice.  Mice were treated with or without 0.2 U/kg or 3 U/kg bleomycin on 
day 0 and then given intraperitoneal injections of 50 µg SAP in 20 mM sodium 
phosphate buffer on days 1 and 2.  On day 3, the mice were euthanized and cells 
from the lungs were collected by BAL. There was no statistically significant 
difference in the number of cells collected from BAL of control, saline, 0.2 U/kg 
bleomycin and buffer, 0.2 U/kg bleomycin and human SAP, or 0.2 U/kg 
bleomycin and mouse SAP (Figure 4.3.10A). Cells collected from the BAL of 
mice were then stained with anti-mouse Ly6G (this stains neutrophils) (Lai et al., 
1998; Landsman et al., 2007) (Figure 4.3.10B). There was an increased number 
of Ly6G-positive cells in the BAL from mice treated with 0.2 U/kg bleomycin and 
buffer compared to the number of Ly6G-positive cells in the BAL from control 
(untreated mice) or saline-treated mice (Figure 4.3.10B).  There was no 
significant difference between the number of Ly6G-positive cells in the BAL from 
mice treated with 0.2 U/kg bleomycin and human SAP or 0.2 U/kg bleomycin and 
mouse SAP when compared to control (untreated mice) or saline-treated mice.  
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However, there was a decreased number of Ly6G-positive cells in the BAL from 
mice treated with 0.2 U/kg bleomycin and human SAP or 0.2 U/kg bleomycin and 
mouse SAP when compared to the BAL from mice treated with 0.2 U/kg 
bleomycin and buffer (Figure 4.3.10B).   
 
We also treated mice with 3 U/kg bleomycin, followed by intraperitoneal 
injections of 50 μl of buffer containing 50 μg human SAP, or 50 μl of buffer, after 
24 and 48 hours.  There was no statistically significant difference between the 
total number of cells collected from the BAL of control or saline-treated mice 
(Figure 4.3.11A).  However, there was an increased number of total cells 
collected in the BAL from mice treated with 3 U/kg bleomycin and buffer or 3 U/kg 
bleomycin and human SAP when compared to the total cells collected in the BAL 
from control or saline-treated mice (Figure 4.3.11A).  There was also an 
increased number of Ly6G-positive cells in the BAL from mice treated with 3 U/kg 
bleomycin and buffer when compared to the number of Ly6G-positive cells in the 
BAL from control or saline-treated mice (Figure 4.3.11B).   However, there was 
no statistically significant difference in Ly6G-positive cells in the BAL from mice 
treated with 3 U/kg bleomycin and human SAP when compared to the Ly6G-
positive cells in the BAL from control or saline-treated mice (Figure 4.3.11B).  
There was a decreased number of Ly6G-positive cells in the BAL from mice 
treated with 3 U/kg bleomycin and human SAP when compared to the number of 
  135 
Ly6G-positive cells in the BAL from mice treated with 3 U/kg bleomycin and 
buffer (Figure 4.3.11B).  
 
We further stained lung sections with Ly6G after BAL to detect neutrophils 
remaining in the lungs after BAL.  For both 0.2 and 3 U/kg bleomycin followed by 
buffer injections, there were more neutrophils observed in the lung sections 
compared to the lung sections from other treatment groups (Figures 4.3.10C and 
4.3.11C).  This indicates that if we had been able to obtain all of the lung 
neutrophils, the difference between bleomycin/buffer injections and 
bleomycin/SAP injections would have been even greater than the differences 
shown in Figure 4.3.10B and 4.3.11B. Our results thus suggest that SAP reduces 
the bleomycin-induced accumulation of neutrophils in the lungs of mice.  
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Figure 4.3.10: SAP decreases the accumulation of Ly6G-positive cells in 0.2 
U/kg bleomycin-treated mouse lungs.  Mice were treated with 0.2 U/kg bleomycin 
using an oropharyngeal technique on day 0.  Mice were then injected with either 
50 μg SAP or an equal volume of buffer on days 1 and 2.  After the mice were 
sacrificed on day 3, cells were collected by BAL. (A) Total number of cells 
collected from BAL of untreated mice (control), mice treated with saline and 
buffer, mice treated with 0.2 U/kg bleomycin and buffer, mice treated with 0.2 
U/kg bleomycin and 50 μg hSAP, or mice treated with bleomycin and 50 μg 
mSAP. (B) Total number of Ly6G-positive cells in the above experimental groups.  
The results are mean ± SEM of the number of cells that positively stained for 
Ly6G (n = 4 for control and mice treated with bleomycin and buffer, n = 5 for mice 
treated with saline and buffer or mice treated with bleomycin and mouse SAP, 
and n = 6 for mice treated with bleomycin and human SAP).  Using the non-
parametric Mann Whitney two tailed t-test, there was an increased number of 
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Ly6G-positive cells in the BAL from bleomycin and buffer when compared to 
control, mice treated with saline and buffer, or mice treated with bleomycin and 
human SAP, with * indicating p < 0.05.  Using the non-parametric Mann Whitney 
two tailed t-test, there was no significant difference between mice treated with 
bleomycin and buffer or mice treated with bleomycin and mouse SAP.  However, 
using the non-parametric Mann Whitney one-tailed t-test, there was a statistically 
significant increase in the number of Ly6G-positive cells in the BAL from mice 
treated with bleomycin and buffer when compared to the number of Ly6G-
positive cells in the BAL from mice treated with bleomycin and mouse SAP.  (C) 
After obtaining cells from BAL, day 3 lung sections from mice treated with 0.2 
U/kg bleomycin and buffer or 0.2 U/kg bleomycin and human SAP were stained 
with anti-mouse Ly6G to detect neutrophils.  Arrows indicate Ly6G-positive cells.  
Bars are 100 μm.  
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Figure 4.3.11: SAP decreases the accumulation of Ly6G-positive cells in 3 U/kg 
bleomycin-treated mouse lungs.  Mice were treated with 3 U/kg bleomycin using 
an oropharyngeal technique on day 0.  Mice were then injected with either 50 μg 
SAP or an equal volume of buffer on days 1 and 2.  After the mice were 
sacrificed on day 3, cells were collected by BAL. (A) Total number of cells 
collected from BAL of untreated mice (control), mice treated with saline and 
buffer, mice treated with 3 U/kg bleomycin and buffer, or mice treated with 3 U/kg 
bleomycin and 50 μg hSAP.  (B) Total number of Ly6G-positive cells in the above 
experimental groups.  The results are mean ± SEM of the number of cells that 
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positively stained for Ly6G (n = 4 for control, mice treated with bleomycin and 
buffer, or mice treated with bleomycin and human SAP, and n = 5 for mice 
treated with saline and buffer).  * indicates a significant difference with p < 0.05 
as determined by non-parametric Mann Whitney two-tailed t-tests.  (C) After 
obtaining cells from BAL, day 3 lung sections of untreated mice (control), mice 
treated with saline and buffer, mice treated with 3 U/kg bleomycin and buffer, or 
mice treated with 3 U/kg bleomycin and 50 μg hSAP were stained with anti-
mouse Ly6G to detect neutrophils.  Arrows indicate Ly6G-positive cells.  Bars are 
100 μm. 
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4.3.9 SAP inhibits the accumulation of Ly6G-positive cells in the lungs of sap-/-
mice treated with bleomycin 
Since SAP decreases the number of neutrophils in the lungs of bleomycin-
treated mice, we examined the effect of SAP on neutrophil accumulation using 
sap-/- mice.  We treated sap-/- mice with 3 U/kg bleomycin, followed by 
intraperitoneal injections of 50 μl of buffer containing 50 μg human SAP, or 50 μl 
of buffer, after 24 and 48 hours.  There was no statistically significant difference 
between the total number of cells collected from the BAL of control or saline-
treated mice (Figure 4.3.12A).  Although the number of cells obtained from the 
BAL of control was greater than the number of cells obtained from the BAL of 
mice treated with 3 U/kg bleomycin and buffer (Figure 4.3.12A), the difference 
was not statistically significant.  However, there was a significant decrease in the 
number of total cells collected in the BAL from sap-/- mice treated with 3 U/kg 
bleomycin and buffer when compared to the total cells collected in the BAL from 
saline-treated mice (Figure 4.3.12A).  There was no statistically significant 
difference between the total number of cells obtained from untreated control 
mice, saline-treated, or 3 U/kg bleomycin and hSAP treated mice.  There was 
also an increased number of Ly6G-positive cells in the BAL from mice treated 
with 3 U/kg bleomycin and buffer when compared to the number of Ly6G-positive 
cells in the BAL from control or saline-treated mice (Figure 4.3.12B).   However, 
there was no statistically significant difference in Ly6G-positive cells from the 
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BAL of mice treated with 3 U/kg bleomycin and human SAP when compared to 
the Ly6G-positive cells in the BAL from control or saline-treated mice (Figure 
4.3.12B).  Although there was a decreased number of Ly6G-positive cells in the 
BAL from mice treated with 3 U/kg bleomycin and human SAP when compared to 
the number of Ly6G-positive cells in the BAL from mice treated with 3 U/kg 
bleomycin and buffer, the difference was not statistically significant.  To further 
examine the neutrophils accumulated in the lungs of sap-/- mice, we stained the 
lung sections after doing the BAL for Ly6G.  We did not detect many neutrophils 
in the lung sections of untreated sap-/- mice or saline-treated sap-/- mice (Figure 
4.3.12C). There were more neutrophils observed in the lung sections of sap-/-
mice treated with bleomycin and buffer when compared to the lung sections from 
other treatment groups (Figures 4.3.12C).  Intraperitoneal injection of human SAP 
decreases the number of neutrophils that accumulate in the lungs of bleomycin-
treated mice (Figure 4.3.12C). Our results thus suggest that SAP reduces the 
bleomycin-induced accumulation of neutrophils in the lungs of mice.  
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Figure 4.3.12: SAP decreases the accumulation of Ly6G-positive cells in the 
lungs of 3 U/kg bleomycin-treated sap-/- mice.  sap-/- mice were treated with 3 
U/kg bleomycin using an oropharyngeal technique on day 0.  Mice were then 
injected with either 50 μg SAP or an equal volume of buffer on days 1 and 2.  
After the mice were sacrificed on day 3, cells were collected by BAL. (A) Total 
number of cells collected from BAL of untreated mice (control), mice treated with 
saline and buffer, mice treated with 3 U/kg bleomycin and buffer, or mice treated 
with 3 U/kg bleomycin and 50 μg hSAP.  * indicates a significant difference with p 
< 0.05 as determined by two-tailed t-tests.  (B) Total number of Ly6G-positive 
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cells in the above experimental groups.  The results are mean ± SEM of the 
number of cells that positively stained for Ly6G (n = 3).  * indicates a significant 
difference with p < 0.05 as determined by one-tailed t-tests.  (C) After obtaining 
cells from BAL, day 3 lung sections of untreated sap-/- mice (control), sap-/- mice 
treated with saline and buffer, sap-/- mice treated with 3 U/kg bleomycin and 
buffer, or sap-/- mice treated with 3 U/kg bleomycin and 50 μg hSAP were stained 
with anti-mouse Ly6G to detect neutrophils.  Arrows indicate Ly6G-positive cells.  
Bars are 100 μm. 
. 
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4.3.10 The lack of SAP increases the number of neutrophils that accumulates in 
the lungs of bleomycin-treated sap-/- mice compared to the bleomycin-treated 
wild-type mice.  
In wild-type mice, the total number of cells collected from the BAL of 
bleomycin-treated mice was significantly more than the total number of cells 
obtained from the BAL of saline-treated mice (Figure 4.3.13A).  On the other 
hand, in sap-/- mice, the total number of cells collected from the BAL of 
bleomycin-treated mice was significantly fewer than the total number of cells 
obtained from the BAL of saline-treated mice (Figure 4.3.13B).    When we 
stained the cells collected from the BAL for the neutrophil marker Ly6G, there 
was an increased number of Ly6G-positive cells in the BAL from wild-type and 
sap-/- mice treated with bleomycin when compared to the number of Ly6G-
positive cells in the BAL from saline-treated mice (Figure 4.3.13B).   However, 
there was no statistically significant difference in the number of neutrophils in the 
BALs from wild-type and sap-/- mice treated with bleomycin. Both wild-type and 
sap-/- mice treated with bleomycin had neutrophils remaining in the lungs after the 
BAL procedure (Figures 4.3.13C).  However, sap-/- mice treated with bleomycin 
had more neutrophils remaining in the lungs compared to the wild-type mice 
treated with bleomycin (Figure 4.3.13C).  Wild-type mice treated with bleomycin 
had neutrophils around the fibrotic-like lung areas, while sap-/- mice treated with 
bleomycin had neutrophils around the fibrotic-like lung areas and scattered 
around the alveolar space (Figure 4.3.13C).  These data suggest that the lack of 
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SAP causes increased retention of neutrophils in the lungs of mice treated with 
bleomycin, and the decreased number of total cells in the BAL of sap-/- mice 
indicates that the lack of SAP causes the adherence of neutrophils in the lungs.  
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Figure 4.3.13 The lack of SAP increases the number of neutrophils remaining in 
the lungs of bleomycin-treated sap-/- mice after bronchoalveolar lavage compared 
to the bleomycin-treated wild-type mice. (A) Bleomycin increases the total 
number of cells in the BAL of wild-type mice while decreases the total number of 
cells in the BAL of sap-/- mice.   Wild-type (C57BL6) and sap-/- mice were treated 
with 3 U/kg bleomycin or an equal volume of saline using an oropharyngeal 
technique on day 0. The mice were sacrificed on day 3, and the cells were 
collected by BAL.  The results are mean ± SEM of the total number of cells 
obtained from BAL (n = 5 for wild-type mice treated with saline, n = 4 for wild-type 
mice treated with bleomycin, and n = 3 for sap-/- mice treated with saline or 
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bleomycin. * indicates a significant difference with p < 0.05 as determined by 
non-parametric Mann Whitney two-tailed t-tests for wild-type mice and one-tailed 
t-test for sap-/- mice. (B) Bleomycin increases the accumulation of neutrophils in 
the lungs of both wild-type and sap-/- mice.  Mice were treated with 3 U/kg 
bleomycin or equal volume of saline using an oropharyngeal technique on day 0. 
The mice were sacrificed on day 3, and the cells were collected by BAL.  The 
results are mean ± SEM of the total number of neutrophils obtained from BAL (n 
= 5 for wild-type mice treated with saline, n = 4 for wild-type mice treated with 
bleomycin, and n = 3 for sap-/- mice treated with saline or bleomycin. * indicates a 
significant difference with p < 0.05 as determined by non-parametric Mann 
Whitney two-tailed t-tests for wild-type mice and a one-tailed t-test for sap-/- mice. 
(C) Bleomycin increases the accumulation of neutrophils in the lungs of both wild-
type and sap-/- mice. After obtaining cells from BAL, lung sections from wild-type 
and sap-/- mice treated with bleomycin or saline were stained with anti-mouse 
Ly6G to detect neutrophils.  Arrows indicate Ly6G-positive cells.  Bars are 100 
μm. 
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4.4 Discussion 
 We found that SAP inhibits cell debris-induced neutrophil spreading and 
TNFα-induced neutrophil adhesion on different extracellular matrices.  However, 
SAP has no effect on the surface levels or the intensity of neutrophil adhesion 
molecules such as CD11b, CD62L, CD18, or CD44 that are affected by 
neutrophil activating factors such as TNF-α, GM-CSF, or fMLP.  SAP also has no 
effect on the production of hydrogen peroxide induced by neutrophil activating 
factors such as PMA, PDBu, fMLP, or TNF-α.  In addition, SAP was unable to 
have any effect on fMLP induced neutrophil migration.  Nevertheless, in our in 
vivo experiment, I saw increased neutrophil accumulation in the lungs of 
bleomycin treated mice.  Intraperitoneal injection of 50 µg of SAP on day 1 and 2 
significantly reduced the number of neutrophils that accumulate in the lungs of 
mice treated with bleomycin.  I further repeated these experiments with sap-/- 
mice. Although not statistically significant, sap-/- mice treated with bleomycin and 
SAP had fewer neutrophils in the BAL than sap-/- mice treated with bleomycin.  
There was a significant decline in the number of neutrophils remaining in the 
lungs after BAL in sap-/- mice treated with bleomycin and SAP when compared to 
the lung sections of the sap-/- mice treated with bleomycin.  There was also an 
increased number of neutrophils remaining in the lungs after BAL in sap-/- mice 
that were treated with bleomycin when compared to the wild-type mice.   
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 Since neutrophil accumulation is a key cause of additional tissue damage 
in acute lung injury, it is important to find therapies that would prevent this 
accumulation.  We have now found that SAP can be used as a therapy in an 
animal model to prevent neutrophil accumulation.   Our hypothesis is that SAP 
acts as an anti-adhesive agent, and therefore, inhibits the accumulation of 
neutrophils in the injured lungs.   There are other pentraxin family proteins that 
also inhibit neutrophil accumulation in animal models of ALI/ARDS (Heuertz and 
Webster, 1997).  The pentraxin proteins such as C-reactive protein (CRP) and 
the pentraxin PTX3 also prevent the number of neutrophils that accumulate in 
injured lungs (Deban et al., 2010; Heuertz and Webster, 1997).  CRP inhibits 
neutrophil adhesion and chemotaxis, and limits the number of neutrophils that 
accumulate in injured lungs (Heuertz and Webster, 1997).  Administering CRP 
intravenously 10 minutes before the intratracheal instillation of the neutrophil 
chemotactic agent C5a dramatically reduced the neutrophil accumulation in lungs 
when examined four hours later (Heuertz et al., 1993). CRP inhibits L-selectin-
mediated neutrophil adhesion on TNF-α activated endothelial cells by inducing L-
selectin shedding from neutrophils.  Further, CRP peptide 201-206 is the critical 
peptide that mediates anti-adhesive action through CD32 (El Kebir et al., 2011). 
Both native and CRP peptide 201-206 prevent neutrophil chemotaxis towards 
fMLP by inhibiting fMLP-induced p38 MAP kinase activity (Heuertz et al., 1999).  
Similarly, the pentraxin PTX3 also prevents neutrophil recruitment in vivo (Deban 
et al., 2010).   Pre-treating mice intravenously with PTX3 reduced the number of 
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neutrophils in acid-induced acute lung injury in mice when examined 3 hours later 
(Mantovani 2010).  PTX3 deficiency also increases the number of neutrophils in 
the lungs of mice treated with lipopolysaccharide (LPS) (Han et al., 2011).  PTX3 
blocks the interaction of P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils 
from interacting with P-selectin on the activated endothelial cells and causes 
neutrophil detachment rather than arrest to prevent neutrophil migration (Deban 
et al., 2010).  
 
 We have now found that SAP also prevents the accumulation of 
neutrophils in the lungs of bleomycin-injured mice.  Since SAP inhibits the 
adhesion of TNF-α-induced neutrophil adhesion, it is probable that SAP reduces 
the accumulation of neutrophils by dampening the interaction of neutrophils with 
extracellular matrices.  We still do not know the neutrophil adhesion receptors 
that are affected by SAP.  We have examined integrin molecules such as CD11b 
and CD18, however, we have not examined beta1 integrin molecules such as 
α2β1, α4β1, α5β1, α6β1, and α9β1 that are found in neutrophils and can 
recognize different extracellular matrices (Birner et al., 1999; Gao and Issekutz, 
1997; Lundberg et al., 2006; Mambole et al., 2010).  Further work is needed to 
understand SAP-induced signaling that prevents TNF-α-induced neutrophil 
adhesion and prevents neutrophil accumulation in the bleomycin-injured mice 
lungs.  Nevertheless, the current findings still show the possible therapeutic effect 
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of SAP on limiting neutrophil accumulation in acute respiratory distress 
syndrome.  
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Concluding Remarks 
 
 Fibrosing diseases and ARDS are major debilitating diseases with high 
mortality rates in many developed countries (King et al., 2011; Perez et al., 2003; 
Wheeler and Bernard, 2007).   There are no effective therapies for fibrosing 
diseases or ARDS, therefore, finding therapies for fibrosing diseases and ARDS 
would help many patients and families.   Inhibiting monocyte-derived cells called 
fibrocytes is one of the ways to reduce the progression of fibrosing diseases.   
The accumulation of immune cells called neutrophils is a major factor that 
worsens the lung injury in ARDS patients, therefore, inhibiting the accumulation 
of neutrophils in the lungs of ARDS patients is one of the ways to reduce the 
progression of ARDS.  In this thesis, I have examined the regulation of fibrocyte 
differentiation and found that a plasma protein called serum amyloid P   that 
already has a potential therapy for fibrosis can also be used as a therapy for 
ARDS.   
 
 In our laboratory, we try to find fibrosing disease therapies by examining 
factors that regulate fibrocyte differentiation.  Since Toll-like receptors (TLRs) are 
present on monocytes, and pathogens that can infect a wound have and/or 
release TLR agonists, in chapter 2, I examined whether TLR agonists affect 
fibrocyte differentiation.  When human peripheral blood mononuclear cells 
(PBMCs) were cultured with TLR3, TLR4, TLR5, TLR7, TLR8 or TLR9 agonists, 
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there was no significant effect on fibrocyte differentiation, even though enhanced 
extracellular tumor necrosis factor (TNF)-α accumulation and/or increased cell 
surface CD86 or antigen presenting cell marker major histocompatibility complex 
(MHC) class II levels were observed. However, all TLR2 agonists tested inhibited 
fibrocyte differentiation without any significant effect on cell survival. Adding 
TLR2 agonists to purified monocytes had no effect on fibrocyte differentiation. 
However, some TLR2 agonists caused PBMCs to secrete a factor that inhibits 
the differentiation of purified monocytes into fibrocytes. This factor is not 
interferon (IFN)-α, IFN-γ, interleukin (IL)-12, aggregated immunoglobulin G (IgG) 
or serum amyloid P (SAP), factors known to inhibit fibrocyte differentiation. TLR2 
agonist-treated PBMCs secrete low levels of IL-6, TNF-α, IFN-γ, granulocyte 
colony-stimulating factor and transforming growth factor (TGF)-β1, but 
combinations of these factors had no effect on fibrocyte differentiation from 
purified monocytes.  Our results indicate that TLR2 agonists indirectly inhibit 
fibrocyte differentiation and that, for some TLR2 agonists, this inhibition involves 
other cell types in the PBMC population secreting an unknown factor that inhibits 
fibrocyte differentiation. Together, these data suggest that the presence of some 
bacterial signals can inhibit fibrocyte differentiation and may thus slow wound 
closure.  The biggest challenge in this project was to find the secreted factor that 
inhibits fibrocyte differentiation.  It was difficult to purify the secreted factor 
because I could not generate large quantities of conditioned media from PBMC 
incubated with TLR2 agonists since I was working with human PBMC.   
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In chapter 3, I have shown that HMWHA potentiates the differentiation of 
human monocytes into fibrocytes, while LMWHA inhibits fibrocyte differentiation.  
Digestion of HMWHA with hyaluronidase produces small hyaluronic acid 
fragments, and these fragments inhibit fibrocyte differentiation.  Monocytes 
internalize HMWHA and LMWHA equally well, suggesting that the opposing 
effects on fibrocyte differentiation are not due to differential internalization of 
HMWHA or LMWHA.  Adding HMWHA to PBMC does not appear to affect the 
levels of the hyaluronic acid receptor CD44, whereas adding LMWHA decreases 
CD44 levels.  The addition of anti-CD44 antibodies potentiates fibrocyte 
differentiation, suggesting that CD44 mediates at least some of the effect of 
hyaluronic acid on fibrocyte differentiation.  The fibrocyte differentiation-inhibiting 
factor serum amyloid P (SAP) inhibits HMWHA-induced fibrocyte differentiation 
and potentiates LMWHA-induced inhibition.  Conversely, LMWHA inhibits the 
ability of HMWHA, interleukin-4 (IL-4), or interleukin-13 (IL-13) to promote 
fibrocyte differentiation.  We hypothesize that hyaluronic acid signals at least in 
part through CD44 to regulate fibrocyte differentiation, with a dominance 
hierarchy of SAP > LMWHA ≥ HMWHA > IL-4 or IL-13.  The biggest challenge in 
this project was to figure out why HMWHA potentiates fibrocyte differentiation 
while LMWHA inhibits fibrocyte differentiation even though they are both 
composed of the same chemical structure.  Many researchers have seen 
opposite effects of HMWHA and LMWHA on different types of cells (Bollyky et 
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al., 2007; McKee et al., 1996), but there are no known mechanisms to explain 
why a simple polysaccharide could have opposite effects.   
 
In chapter 4, examining the effect of SAP on neutrophils led us to the 
exciting possibility of using SAP as a therapy for ARDS.  We found that SAP 
inhibits cell debris-induced neutrophil spreading and TNFα-induced neutrophil 
adhesion on different extracellular matrices.  Further, in vivo, we found that 
intraperitoneal injection of exogenous SAP inhibits the accumulation of 
neutrophils induced by bleomycin in both wild-type and sap-/- mice.  However, 
SAP has no effect on the classical neutrophil adhesion molecules, production of 
hydrogen peroxide, or the migration of neutrophils.  The biggest challenge in this 
project was to find the adhesion molecules that were affected by SAP.  SAP 
inhibits TNF-α-induced neutrophil adhesion on plate assays, but it was difficult to 
mimic this interaction in solution and examine neutrophil adhesion molecules.  In 
the future, we could examine other neutrophil adhesion molecules that may be 
affected by SAP.  We could also examine the effect of SAP on TNF-α-induced 
neutrophil adhesion in a static condition rather than a non-static condition to truly 
observe the detachment of neutrophils caused by SAP.  Since C-reactive protein 
(CRP) affects a MAP kinase pathway, we could also examine the effect of SAP 
on this pathway.   
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